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ABSTRACT OF DISSERTATION
OXIDATIVE DAMAGE TO DNA IN ALZHEIMERS DISEASE

Previous studies from our laboratory and others show a significant increase in
levels of both nuclear and mitochondrial DNA and RNA oxidation in vulnerable brain
regions in the progression of Alzheimer’s disease (AD). Although total DNA oxidation
is increased in AD it remains unclear whether oxidative damage is widespread throughout
the genome or is concentrated to specific genes. To test the hypothesis that specific genes
are more highly oxidized in the progression of AD, we propose to quantify the percent
oxidative damage in genes coding for proteins shown to be altered in the progression of
AD using quantitative/real-time polymerase chain reaction (qPCR/ RT-PCR). To further
test the hypothesis that diminished DNA repair capacity in the progression of AD
contributes to increased DNA oxidation we will use custom PCR arrays and qPCR,
Western blot analysis and activity assays to quantify changes in enzymes involved in
base excision repair (BER).
In order to carry out these studies tissue specimens from superior and middle
temporal gyri (SMTG) and inferior parietal lobe (IP), as well as, a non-vulnerable region,
the cerebellum (CER) will be analyzed from normal control (NC) subjects and subjects
throughout the progression of AD including those with preclinical AD (PCAD), mild
cognitive impairment (MCI), and late stage AD (LAD). We will also analyze specimens
from diseased control subjects (DC; Frontotemporal dementia (FTD) and dementia with
Lewy bodies (DLB)) to determine if the changes we observe in AD are specific.

KEYWORDS: Alzheimer’s disease (AD), oxidative stress, base excision repair, DNA
oxidation
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1. Alzheimer’s Disease (AD)
1.1.1. Discovery and Incidence
Alzheimer’ disease (AD) is a progressive neurodegenerative disorder, first described
by Alois Alzheimer in 1906 at the 37th meeting of South-West German Psychiatrists in
Tubingen. Alzheimer’s lecture at Tubingen described the symptomatology, progression
and course of disease over a period of about five years as well as the histological and
morphological features of the brain after the death of a patient, Auguste Deter. The
clinical characteristics of Auguste D. included sleep disorders, memory loss,
aggressiveness, aphasia and progressive confusion. Histopathologically, Alzheimer
reported the presence of intracellular and extracellular aggregates in the brain of Auguste
D after autopsy. Intracellular aggregates composed of hyperphosphorylated microtubule
associated tau protein (neurofibrillary tangles) and extracellular aggregates of β-amyloid
peptide (senile plaques) are now recognized as two of the main pathological markers of
AD (Hippius and Neundorfer, 2003). Despite discovery a century ago, it is only during
the last few decades that research into the symptoms, causes and treatment of AD has
gained momentum as the number of people affected by this disease increased
dramatically.
At present, AD affects 5.2 million Americans with an estimated cost of ~200 billion
dollars annually. One in 8 Americans age 65 and over suffers from AD, and at present
there is no way to prevent, cure or even slow the progression of the disease (Burns and
Iliffe, 2009; Hebert et al., 2013). Death of patients with AD increased by 68% between
2000 and 2010 whereas death by other major diseases including breast cancer, prostate
1

cancer, heart disease, stroke and HIV decreased (Thies and Bleiler, 2013). After
diagnosis, most people with AD survive 4-8 years, on average, with some surviving as
long as 20 years. On average, 40% of this time is spent in the most severe stage of the
disease when a patient is completely incapable of taking care of themselves. Although
AD is the sixth leading cause of mortality in the United States, death is generally due to
secondary illness/infection Unless medical breakthroughs identify ways to prevent or
more effectively treat the disease, the number of AD patients in the US is expected to
triple by the year 2050, with annual costs that may singlehandedly create a massive
health care crisis (Burns and Iliffe, 2009; Thies and Bleiler, 2011, 2013).
1.1.2. Clinical Characteristics
The major difficulty in the diagnosis of AD is the lack of laboratory tests to confirm
AD in a patient antemortem. Clinical diagnosis of AD is based on medical history and
clinical examination, coupled with laboratory tests and brain imaging (computed
tomography or magnetic resonance imaging) to exclude other forms of dementia. The
criteria set by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), and the National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDSADRDA) are the two most common clinical criteria used for the diagnosis of AD. These
criteria state that the leading diagnostic element for AD is the steady onset and
progression of dementia in a patient with no other known cause of dementia. Eventually,
this steady decline across multiple cognitive domains leads to late stage dementia where
the patient is almost totally dependent on caregivers for even the most basic functions
(Brookmeyer et al., 2002; Burns and Iliffe, 2009; Yaari and Corey-Bloom, 2007).
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The DSM-IV criteria require an insidious onset along with cognitive function
decline, memory impairment and a second cognitive deficit such as aphasia, apraxia,
agnosia or impairment of executive functioning. DSM-IV criteria require that other
psychiatric, neurological, metabolic or systemic diseases be excluded as a reason for
impairments in social or occupational functioning before the confirmation of a diagnosis
for AD. In comparison, the NINCDS-ADRDA guidelines are more comprehensive and
provide a disease progression sequence for AD classified as probable, possible and
definite AD. Probable and possible AD diagnosis can be made antemoretem whereas
definite AD can only be identified postmortem. Probable AD is characterized by deficits
in two or more cognitive domains, progressive memory deterioration, preserved
consciousness and onset between ages 40-90 in the absence of alternative reasons for the
symptoms. “Possible AD” patients display atypical onset of dementia along with the
presence of additional signs of dementia. Definite AD can only be diagnosed postmortem
by a combination of clinical diagnosis and neuropathological evaluation of the brain after
autopsy. The average time from onset of AD to death varies from 4 to 10 years depending
on the age of the patient at onset (Dubois et al., 2007; Khachaturian and Radebaugh,
1996; McKhann et al., 1984; Yaari and Corey-Bloom, 2007).
1.1.3.

Pathological Features

Pathologically, a gross visual inspection of an AD brain displays the presence of
marked cerebral cortical atrophy epitomized by widening of the sulci and shrinkage of
the gyri (Figure 1.1). Several microscopic changes distinctive of AD include loss of
neuronal and synaptic densities in the hippocampus, amygdala, entorhinal cortex,
neocortex, and nucleus basalis of Meynert. Neuropathologically, the AD brain is

3

characterized principally by the presence of two distinctive hallmarks: senile plaques
(SP) and neurofibrillary tangles (NFT) (Khachaturian and Radebaugh, 1996; Yaari and
Corey-Bloom, 2007). Neither of the neuropathological hallmarks is unique to AD and
are also seen in cognitively normal individuals although AD subjects show considerably
higher densities. NFTs are also observed in patients with other neurodegenerative
diseases including frontotemporal dementia (Braak and Braak, 1991; Graff-Radford and
Woodruff, 2007; Grossman, 2002).
Two different types of senile plaques can be observed in the AD brain: neuritic and
diffuse. Neuritic plaques contain tendrils or dense cores of fibrillar amyloid surrounded
by dystrophic neurites, reactive astrocytes and activated microglia. Diffuse plaques on the
other hand are amorphous in appearance, have no abnormal neurites and contain little or
no fibrillar amyloid. Senile plaques (SP) are principally composed of insoluble amyloid
beta (Aβ) peptides specifically a mixture of Aβ1-42/43 (> 95%) and small amounts of Aβ140

(reviewed in (Markesbery and Lovell, 2006)). Amyloid β is a ~4 kDa peptide

containing 11-15 amino acids from the transmembrane domain and 28 amino acids from
the extracellular domain of the amyloid precursor protein (APP). On average, 90% of the
larger APP protein is cleaved by α-secretase generating a large secreted derivative sAPPα
and an 83 amino acid fragment CTFα. CTFα subsequently gets cleaved by γ-secretase
producing the benign p3 fragment and a cytosolic element, APP intracellular domain
(AICD). The remaining 10% of APP is cleaved first by β-secretase to produce a large
secreted derivative sAPPβ and a membrane bound 99 amino acid fragment CTFβ. γsecretase cleaves the CTFβ fragment further to generate AICD and Aβ40 (~80-90%) or
Aβ42 (~5-10%). Rapid nucleation of Aβ1-42/43 into amyloid fibrils is considered to be the

4

seed for aggregation and consequent deposition of Aβ in SPs. Although studies have
shown evidence of Aβ’s involvement in synaptic dysfunction, disruption of neural
connectivity and neuronal death, only weak correlations have been observed between the
extent and distribution of Aβ deposition and the clinical manifestation of AD
(Khachaturian and Radebaugh, 1996; reviewed in Murphy and LeVine, 2010; Selkoe,
2001).
NFTs are composed of paired helical filaments (PHFs) and 15 nm straight filaments.
PHFs which can also be present in neutrophil threads and dystrophic neurites principally
contain abnormally hyperphosphorylated isoforms of tau, a protein associated with
microtubules. Customarily, tau binds to microtubules supporting their formation and
stabilization. Hyperphosphorylated tau is unable to bind microtubules making them
unstable leading to their disintegration. Unbound tau then bundles together to form
neurofibrillary tangles. Tau pathology has also been observed in patients with
Parkinson’s disease (PD), progressive supranuclear palsy and frontotemporal dementia
(Khachaturian and Radebaugh, 1996). Unlike SPs, there is a strong correlation between
number of NFTs and cognitive deficits and neuronal loss in an AD patient’s brain. NFTs
exhibit a characteristic distribution in the brain allowing differentiation into six stages
described by the Braak staging scheme (Braak and Braak, 1991). The presence of NFT’s
primarily in the transentorhinal region of the brain indicates Braak stages I and II
(cognitively normal subjects) whereas stages III and IV indicate progression of tangles
into limbic regions such as the hippocampus, and V and VI when there's extensive tangle
formation in neocortical regions (late AD patients) (Braak and Braak, 1991; GrundkeIqbal et al., 1986; Khachaturian and Radebaugh, 1996).
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It has been suggested that progressive inflammation and oxidative stress may be
major factors leading to synaptic dysfunction and the loss of neuronal integrity which
usually pave the way for the appearance of amyloid plaques and neurofibrillary tangles in
the brains of AD patients (Jicha and Markesbery, 2010; Khachaturian and Radebaugh,
1996). The neuropathological hallmarks of AD can be evaluated by several diagnostic
criteria including the National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDSADRDA) criteria (McKhann et al., 1984), the Consortium to Establish a Registry for
Alzheimer’s disease (CERAD) criteria (Mirra, 1997) and the National Institute of AgingReagan Institute (NIA-RI) consensus criteria (NIA-Reagan-Institute, 1997). The
NINCDS-ADRDA criteria require a certain number of SP in an age-dependent manner in
the neocortex. In this criteria, the type of SP is not identified, changes in the entorhinal
cortex, hippocampus or amygdala are not considered and presence of NFTs is only
considered for patients under the age of 50 (Markesbery, 1997a; McKhann et al., 1984).
The CERAD criteria is based on the semiquantification of neuritic plaques (NPs) as
sparse, moderate or frequent in three brain regions: middle frontal gyrus, superior and
middle temporal gyri and inferior parietal lobule in individuals in three different age
categories: less than 50, 50 to 75 and over 75. The criteria also require correlation of the
pathological characteristics with a clinical diagnosis of dementia. The CERAD criteria
fail to consider the presence of NFTs and the changes in the hippocampus, entorhinal
cortex and amygdala for AD diagnosis(Markesbery, 1997a; Mirra, 1997). The NIA-RI
consensus criteria consider the correlation of both SPs and NFTs with AD. This criteria is
based on the semiquantification of NPs (CERAD criteria), determination of extent of
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NFTs in hippocampus and neocortex (Braak score) and clinical diagnosis of dementia
(Geddes et al., 1997; NIA-Reagan-Institute, 1997).
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Figure 1.1. Macroscopic and microscopic changes in the human brain associated with
Alzheimers disease including

(A) widened sulci and shrunken gyri in the coronal

sectioned AD brain (right)) compared to the age matched normal control subject (left),
(
(B) staining of senile plaques (SPs) and (C) staining of neurofibrillary tangles (NFTs)
(Adapted from (Lovell
Lovell et al., 1993
1993; Lovell et al., 1998)).
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1.1.4. Risk Factors
Several factors contribute to the probability of a person developing AD including
age, genetic predisposition and head trauma. Aging is considered the primary risk factor
for AD (Evans et al., 1989) and the risk of developing the disease dramatically increases
with age. After age 65 the possibility of developing AD doubles every five years and
reaches 50% in people aged 85 and over (Kawas et al., 2000). Family history is the next
important risk factor in the incidence of AD (Henderson, 1986). There is a ~ 10-14%
higher risk of AD in people who have close relatives (parent, brother, sister or child)
suffering from the disease compared to unrelated individuals (Burns and Iliffe, 2009).
The expression of Apolipoprotein E (ApoE), a protein involved in cholesterol transport in
the bloodstream, has also been linked with the incidence of late-onset AD. There are
three isoforms of ApoE: ε2, ε3 (most common) and ε4. Expression of the ε4 isoform of
ApoE is associated with increased risk of AD. Studies show the existence of one or two
copies of the ApoE- ε4 gene in 40-65% of people diagnosed with AD (Farrer et al., 1997;
Hollingworth et al., 2011; Saunders et al., 1993). On the other hand, factors such as high
educational and occupational attainment, high levels of social and cognitive engagement,
postmenopausal estrogen replacement therapy, and long-term use of anti- inflammatory
drugs have been implicated in decreasing the risk of AD (Khachaturian and Radebaugh,
1996; Mortimer et al., 2003; Prasad et al., 2002; reviewed in Murphy and LeVine, 2010;
Zhang et al., 1990). Additionally, traumatic brain injury, smoking and obesity have been
implicated in increasing the risk of AD (Gustafson et al., 2003; Merchant et al., 1999;
Mortimer et al., 1985; Mortimer et al., 1991; Ott et al., 1998). Less than 1% of AD
patients are affected by Familial Alzheimer's disease (FAD) or early-onset Alzheimer's,
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an inherited, rare form of the disease which can occur as early as age 35. Mutations in
APP (located on chromosome 21) or presenelin-1 (PS-1) (located on chromosome 14) or
presenelin-2 (PS-2) (located on chromosome 1) have been shown to be the cause of FAD
(Hollingworth et al., 2011; Xie and Tanzi, 2006). Individuals with Down’s syndrome
have an extra copy of the APP gene which could be a factor in the development of ADassociated pathology in them as early as age 40 (Mann et al., 1990; Thies and Bleiler,
2013).
1.1.5. Early Stages
Increasing evidence suggests that in an Alzheimer’s patient, pathological changes in
the brain may begin decades before the appearance of clinical symptoms (Fagan et al.,
2005; Lange et al., 2002). In a neuropathological study conducted in 1997, Braak and
Braak reported the presence of NFTs in subjects as young as 40 years old (Braak and
Braak, 1997). Thus there has been considerable interest in the diagnosis and
characterization of the preliminary phases of AD. Identification of the early phases of AD
may help in the identification of the pathogenesis of AD thus expediting
enhancement/discovery of early pharmacological intervention and possible reversal of the
disease. Based on both pathological and/or clinical diagnosis, AD can be broadly
classified into the following stages:
Amnestic Mild Cognitive Impairment (MCI):
MCI is the phase between normal aging and early dementia characterized as the
earliest detectable clinical phase of AD. Petersen et al. define amnestic MCI patients as
individuals with symptoms which include: (a) memory impairment observed over time
corrected for age and education (b) normal general cognitive function (c) intact activities
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of daily living and (d) the subject not meeting criteria for dementia (DeCarli, 2003;
Maynard et al., 2010). Thus, patients with MCI exhibit characteristics of both clinically
normal individuals as well as AD patients. MCI subjects go on to develop AD with a
conversion rate of ~ 15% per year. Histopathologically, MCI subjects show a significant
increase in neuritic plaques in neocortical regions and a significant increase in
neurofibrillary tangles in the hippocampus, entorhinal cortex and amygdala, compared to
NC subjects. Braak staging scores for MCI subjects are usually in the range of III-IV
(DeCarli, 2003; Petersen et al., 2009; Wang et al., 2005).
Preclinical AD (PCAD):
The criteria for identifying PCAD subjects are not well-defined. Schmitt et al. define
subjects with PCAD as individuals who show normal antemortem psychometric test
scores adjusted for age and education, but at autopsy demonstrate distinct AD pathology
that meets NIA-RI intermediate or high-likelihood criteria for the histopathological
diagnosis of AD. PCAD subjects demonstrate Braak staging scores of III or higher,
moderate or frequent neuritic plaque scores, neuronal hypertrophy, increased synaptic
plasticity and alterations in zinc transporters (Bradley et al., 2010; Schmitt et al., 2000).
Preclinical AD (PCAD) subjects are diagnosed based on the tentative criteria set by the
UK-ADC which includes (a) pronounced AD pathology with Braak scores of III-V and
(b) antemortem psychometric tests in the normal range when corrected for age and
education (Schmitt et al., 2000).
1.1.6. Etiology
The etiology and pathogenesis of AD are unknown at present. In order to explain the
pathology of the disease, several hypotheses have been advanced, including genetic
11

abnormalities, slow or latent virus disorder, deficits in energy metabolism, glutamate
excitotoxicity, defects in mitochondria, the amyloid cascade, tau abnormality,
acetylcholine deficiency, trace element neurotoxicity or oxidative stress. Currently, none
of these hypotheses alone can adequately explain the clinical and pathological aspects of
AD. It is probable that AD is a multifactorial disease and a combination of multiple
hypotheses may more adequately explain the pathogenesis of the disease. Multiple
studies have shown presence of oxidative stress in AD patients, even though the exact
role of oxidative stress in the pathogenesis of AD is not known (Khachaturian and
Radebaugh, 1996; Markesbery, 1997b; Thies and Bleiler, 2011). The oxidative stress
hypothesis is described below as the work in this thesis examines the oxidative damage
caused to biomolecules when they undergo oxidative stress.
1.2. Oxidative Stress and AD
1.2.1 Reactive Oxygen Species (ROS)
A free radical is an atom or molecule containing one or more unpaired electrons in
its outer shell. Free radicals are produced both exogenously and endogenously in the
human body. Oxygen free radicals (the most common free radicals present in the human
body) including superoxide (O2• –), hydroxyl (•OH), peroxyl (RO2• –) and alkoxyl (•OR)
radicals along with non-radicals such as hypochlorous acid (HOCl), ozone (O3),
peroxynitrite (ONOO-), singlet oxygen (1O2) and H2O2 that can be easily converted to
radicals, are collectively labeled as “reactive oxygen species” (ROS) (Apel and Hirt,
2004; Murphy, 2009). Reactive oxygen species (ROS) such as •OH, and O2•
predominantly

produced

during

normal

cellular

phosphorylation during normal cellular respiration.
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metabolism

like

–

are

oxidative

In a normally functioning cell,

approximately 2% of oxygen consumed during oxidative phosphorylation is converted to
ROS (reviewed in (Murphy, 2009)). In a normal biological system, excess ROS are
scavenged by enzymes such as superoxide dismutase, glutathione peroxidase and catalase
among others, making them less detrimental. Superoxide radicals are converted to
hydrogen peroxide by antioxidant enzymes, superoxide dismutases. Hydrogen peroxide
thus produced can be rendered harmless either by conversion to water and molecular
oxygen by glutathione peroxidase/ catalase or can diffuse into the cytoplasm and react
with Fe (Fenton’s reaction) or Cu (Haber-Weiss reaction) present to generate hydroxyl
radicals which cause oxidative damage (Figure 1.2) (Markesbery, 1997b; Wiseman and
Halliwell, 1996). ROS can also be produced by ionizing or ultraviolet radiation, smoking,
air pollution and other biological processes such as inflammation (Cooke et al., 2003;
Markesbery, 1997b; Markesbery and Lovell, 2006; Wiseman and Halliwell, 1996). As a
result of its high oxygen consumption (1/5 of consumed oxygen) , substantial lipid
content, relatively high levels of redox active metals, and the comparative inadequacy of
antioxidant enzymes, the brain is especially susceptible to damage by free radicals
(Markesbery, 1997b).
1.2.2. Oxidative Stress
A discrepancy between the production of ROS and the biological system’s ability to
eliminate these reactive intermediates results in oxidative stress and subsequently
mitochondrial dysfunction and neuronal damage. Oxidative stress has been linked to
aging and various age-associated neurodegenerative diseases including AD, Parkinson’s
disease and amyotrophic lateral sclerosis (Bowling et al., 1993; Harman, 1956; Jenner,
2003; Markesbery, 1997b). Studies have suggested that the late life onset and slow
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progression of these conditions could thus be accounted for by cumulative and
irreversible oxidative damage over time. Oxidative stress can cause damage to most
biomolecules in the body. Some biomarkers of oxidative damage are 8-hydroxyguanosine
(oxidative damage of nucleic acids), protein carbonyls, 3-nitrotyrosine (oxidative damage
of proteins) and 4-hydroxynonenal and malondialdehyde (oxidative damage of lipids).
Several of the above markers have been detected in multiple vulnerable regions of the
brains of LAD and MCI patients, leading to the theory that oxidative stress has a
prominent role in the early pathogenesis of AD (Cooke et al., 2003; Markesbery, 1997b;
Markesbery and Lovell, 2006).
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1.2.3. Lipid Peroxidation and Protein Oxidation
Biological membranes are composed of 30-80% lipids by mass and are vitally
important for the preservation of cellular homeostasis. Elevated levels of both lipid and
protein oxidation have been reported in several neurodegenerative diseases such as AD
and Parkinson’s disease (Bradley et al., 2010; Jenner, 2003; Markesbery, 1997b;
Markesbery and Carney, 1999; Williams et al., 2006; Zhou et al., 2008). Measurements
of thiobarbituric acid reactive substances (TBARS), changes in polyunsaturated fatty
acids (PUFA) and breakdown products of PUFA (aldehydes and isoprostanes) are
indicators of lipid peroxidation in a biological system. Peroxidation of lipids produces
multiple aldehydic by-products including malonialdehyde, C3-C10 straight chain
aldehydes and α,β-unsaturated aldehydes such as 4-hydroxynonenal (HNE) and acrolein.
HNE and acrolein are neurotoxic, can form adducts with DNA/protein thus affecting their
function and are frequently used as markers of lipid oxidation. Levels of HNE and
acrolein have been shown to be elevated in AD brain and CSF (Bradley et al., 2010;
Bruce-Keller et al., 1998a; Bruce-Keller et al., 1998b; Montine et al., 1998; Williams et
al., 2006). Previous studies show that isoprostanes, produced by free-radical peroxidation
of arachidonic acid are also elevated in the CSF of AD subjects as compared to control
subjects (Milne et al., 2005; Montine et al., 1998).
Oxidative damage to proteins causes a decrease in protein activity; probably due to
elevation in protein carbonylation levels, side chain oxidation and protein crosslinking
(Poon et al., 2004; Soskic et al., 2008). Protein oxidative damage is principally analyzed
by the hydrazide reactive protein carbonyl analysis (Smith et al., 1991). Previous studies
show the presence of nitrotyrosine in NFT’s and an elevation in protein carbonyl levels in
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the hippocampus and the frontal and parietal lobes in the brain of AD patients compared
to control subjects (Hensley et al., 1995; Smith et al., 1991; Smith et al., 1997).
1.2.4. Nucleic Acid Oxidation
The attack of ROS on DNA can generate more than 20 kinds of oxidized base
adducts

including

8-hydroxyguanine

(8-OHG),

2,6-diamino-4-hydroxy-5-

formamidopyrimidine (fapy guanine), 8-hydroxyadenine (8-OHA), 4,6-diamino-5formamidopyrimidine (fapy adenine) 5-hydroxycytosine (5-OHC) and 5-hydroxyuracil
(5-OHU) (Figure 1.3A) (Cooke et al., 2003; Gabbita et al., 1998; Markesbery and
Carney, 1999). ROS such as hydroxyl radical reacts with the double bonds in both
purines and pyrimidines leading to the formation of purine-OH (at positions C4, C5 or
C8) or pyrimidine-OH (at position C5 or C6) adducts. 8-hydroxyguanine (-OHG) /8hydroxyadenine (8-OHA) are produced by oxidation of the C8-hydroxyl radical formed
by the reaction of •OH radical with the C8-N9 double bond of purines. In the absence of
oxygen however, 2,6-diamino-4-hydroxy-5-formamidopyrimidine (fapyguanine; fapyG)
and 4,6-diamino-5-foramidopyrimidine (fapyadenine; fapyA) are formed due to
imidazole ring opening at the C8-N9 site (Figure 1.3B and 1.3C). 5-hydroxycytosine (5OHC) is formed by dehydration of cytosine glycol and 5-hydroxyuracil (5-OHU) is
produced by deamination of cytosine glycol. Cytosine glycol is in turn produced by
reduction of the pyrimidine-OH adduct with water (Figure 1.3D) (Cooke et al., 2003;
Steenken, 1989a, b). Bulky exocyclic adducts are formed when DNA base modifications
are caused by lipid peroxidation products including 4-hydroxynonenal and acrolein.
These modifications in DNA bases could cause mispairing during DNA replication
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eventually leading to altered protein synthesis (Markesbery and Carney, 1999; Wang et
al., 2005).
As a result of its high electron density and low oxidation potential, guanine (G) is the
most vulnerable to oxidation among the five DNA bases (Bhattacharya and Barton, 2001;
Candeias and Steenken, 1989; Steenken and Jovanovic, 1997). Oxidation of guanine
leads to the formation of 8-OHG under elevated oxygen levels and fapyguanine under
hypoxic conditions (Steenken and Jovanovic, 1997). The predominant biomarker for
oxidative damage of DNA is the major oxidation product of guanine, 8-OHG. 8hydroxyguanine production can lead to its mispairing with adenine and even misreading
of adjacent bases during replication (Cheng et al., 1992). Previous studies have shown an
increase in levels of 8-OHG and 8-OHA in nDNA from various regions of the brain
including the temporal, parietal and frontal lobes of AD patients even in the earlier stages
of the disease as compared to normal control subjects (Gabbita et al., 1998; Wang et al.,
2008).
Increased oxidation of nuclear and mitochondrial DNA, and RNA by ROS especially
the hydroxyl radical (•OH), have been implicated in multiple neurodegenerative diseases
including AD, PD and DLB (Bowling et al., 1993; Gabbita et al., 1998; Lyras et al.,
1998; Wang et al., 2005; Zhang et al., 1999; Zhou et al., 2008). Although oxidation in
both nuclear and mitochondrial DNA in AD subjects has been extensively studied, there
are few studies that focus on RNA oxidation in AD. Shan et al. showed an elevation of 8OHG in mRNA and a corresponding decrease in protein expression in LAD subjects
compared to NC subjects (Shan et al., 2007; Shan and Lin, 2006). Messenger RNA
oxidation may result in premature translation termination and reduction in activity of
18

translated mRNAs (Shan et al., 2007; Shan et al., 2003). Due to the lack of protective
histones, lack of rich antioxidant system, diminished DNA repair capability and the
proximity to the site of generation of ROS, mitochondrial DNA (mtDNA) appears to be
more vulnerable to oxidative damage compared to nuclear DNA. Previous studies have
found ~ 2-10 fold higher levels of oxidized bases in mtDNA compared to nDNA
(Mecocci et al., 1993; Wang et al., 2005). Oxidative damage to DNA by ROS can result
in base alterations, single and double strand breaks, DNA-DNA/DNA-protein crosslinks,
sister-chromatid exchange and translocation. These changes in the DNA can lead to
altered protein expression which in turn may cause apoptosis.
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1.3. DNA Repair Pathways
In healthy individuals, damaged DNA is repaired via multiple DNA repair pathways
including base excision repair (BER), nucleotide excision repair (NER), double strand
break repair (DSB) and mismatch repair (MMR). A brief description of these repair
pathways is given below.
1.3.1. Base Excision Repair (BER) Pathway
The primary pathway for DNA repair of small base modifications such as alkylation,
deamination and oxidation is the BER pathway. The BER pathway proceeds via removal
of damaged DNA bases by substrate specific glycosylases including oxoguanine DNA
glycosylase

(OGG1)

and

uracil

DNA

glycosylase

(UNG),

incision

of

the

apurinic/apyrimidinic site by endonucleases such as AP endonuclease (APE1), followed
by incorporation of the correct nucleotide(s) by DNA polymerase and strand ligation by
DNA ligase (Figure 1.4). The BER pathway is further divided into two sub-pathways:
short-patch BER (single nucleotide excision) and long-patch BER (repair patch size of 28 nucleotides). It is postulated that in age-related neurodegenerative diseases like AD, the
DNA repair system loses its capacity leading to accumulated oxidative DNA damage
(Lovell et al., 2000; Markesbery and Lovell, 2006; Moreira et al., 2008; Weissman et al.,
2007).
Proteins implicated in aging/AD from the base excision repair (BER) pathways
including 8-oxoguanine DNA glycosylase (OGG1), Uracil-DNA glycosylase (UNG),
APE nuclease1 (APE1), Polymerase (DNA directed), beta (POLB), Flap structurespecific endonuclease 1 (FEN1), Poly (ADP-ribose) polymerase 1 (PARP1) and X-ray
repair complementing defective repair in Chinese hamster cells 1 (XRCC1) were
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investigated in this study. Previous studies have shown that 8-hydroxyguanine or its
isomeric form 7,8-dihydro-8-oxoguanine is the major DNA lesion resulting from
nuclear/mitochondrial DNA oxidation (Cooke et al., 2003; Loft et al., 2008; Moreira et
al., 2008). Unrepaired 8-hydroxyguanine induces G:C → A:T transversion mutations
during replication or in the case of postmitotic cells like neurons, it may lead to
diminished cellular activity and death. 8-oxoguanine DNA glycosylase (OGG1) is the
principal enzyme for excision of 8-oxoguanine in the initiation step of the BER pathway
for both nuclear and mitochondrial DNA lesions. Previous studies show a decrease in
gene expression, protein levels and incision activity of nuclear OGG1 in vulnerable brain
regions of patients suffering from AD (Dorjsuren et al., 2011; Lovell and Markesbery,
2007b; Weissman et al., 2007). Mao et al. showed that there was complete loss of 8-oxoguanine glycosylase activity in vitro with a single base deletion (C796) observed in a
subset of AD subjects whereas, two different single base substitutions resulted in reduced
glycosylase activity in vitro (Mao et al., 2007). Another common lesion observed in DNA
is the introduction of uracil into genomic DNA by deamination of cytosine. Unrepaired
uracil in DNA leads to a C→T transition mutations during replication. Uracil-DNA
glycosylase (UNG) initiates the BER pathway in cases of misincorporation of uracil into
DNA and is the primary enzyme for removal of uracil from DNA. UNG protein levels
and protein activity are lower in AD subjects compared to clinically normal subjects
(Hegde et al., 2008; Kruman et al., 2004; Weissman et al., 2007). Both OGG1 and UNG
lead to the creation of an apurinic/apyrimidinic (AP) site after excision of the damaged
base. APE nuclease1 (APE1), a multifunctional DNA repair enzyme, primarily functions
as a nuclease in the second and rate limiting step in the BER pathway. APE1 removes the
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AP site by cleaving the DNA strand 5´ to the AP site leaving a gap in the DNA strand
with a 3´ OH and a 5´ deoxyribose phosphate terminus (Hegde et al., 2008; Weissman
et al., 2007). Studies have shown an increase in the expression of APE1 but no significant
changes in AP-site incision activity or APE1 protein levels in the brain of AD patients
compared to normal control subjects (Burns and Iliffe, 2009; Davydov et al., 2003;
Weissman et al., 2007).
Polymerase (DNA directed), beta (POLB) is implicated occasionally in de novo
DNA synthesis. Recent studies indicate POLB may be involved early in the pathogenesis
of AD. An increase in expression of POLB was observed in neurons with minor ADrelated neuropathology but the protein expression reduced with severity of pathology
(Copani et al., 2006; Weissman et al., 2007). X-ray repair complementing defective
repair in Chinese hamster cells 1 (XRCC1) facilitates the repair and rejoining of DNA
strand breaks and repairs gaps left during BER. Doğru-Abbasoğlu et al. found that the
Trp allele of the functional XRCC1 Arg194Trp genetic polymorphism occurs more
frequently in AD patients than in clinically normal individuals (Dogru-Abbasoglu et al.,
2007; Woodhouse and Dianov, 2008). Poly (ADP-ribose) polymerase 1 (PARP1) is
activated when oxidative damage leads to single strand or double strand breaks of DNA.
PARP1 acts as a catalyst in two processes: (a) cleavage of NAD+ into adenosine 5'diphosphoribose (ADP-ribose) and nicotinamide and (b) the covalent attachment of ADPribose polymers to nuclear proteins such as histones. An increase in gene expression of
PARP1 in AD patients, leading to massive NAD+ depletion and subsequent cell death,
has been reported (Reddy P.V., 2006). Flap endonuclease 1 (FEN1) acts as an 5’exonuclease and gap endonuclease in DNA replication and long patch BER respectively.
27

FEN1 helps remove the flap segment formed during long-patch BER by addition of
nucleotides around the damaged base by POLB. DNA ligase then seals the gap that
remains after repair (Podlutsky et al., 2001a; Zheng et al., 2011).
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Figure 1.4. Base Excision Repair (BER) Pathway
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1.3.2 Nucleotide Excision Repair (NER) Pathway
The NER pathway is the principal repair mechanism for removal of bulky helix
distortions such as lesions made by UV-induced pyrimidine dimers, intra-strand
crosslinks, protein DNA crosslinks, and bulky chemical adducts. Multiple enzymes
including xeroderma pigmentosum, EF-hand protein, replication protein A (RPA) and the
UV-damaged DNA-binding protein (UV-DDB) are functional in the NER pathway. In
humans, multiple inherited disorders caused by mutations in NER enzymes have been
diagnosed. Studies show that in non-replicating cells such as neurons, NER is highly
diminished. (von Kobbe et al., 2003). Xeroderma pigmentosum complementation group
A (XPA), an enzyme in the nucleotide excision repair (NER) pathway, has also been
implicated in aging. Subjects with XP, a rare autosomal recessive disease characterized
by hypersensitivity of skin to sunlight and an increased risk of skin cancer of sun-exposed
parts of the body, show a defect in the early step of nucleotide-excision repair.
Xeroderma pigmentosum consists of eight different complementation groups (groups A–
G, and a variant). Of all the complementation groups, Group A (XPA) is the most severe
clinical form (Bennett et al., 1997).
1.3.3. Double Strand Break (DSB) Repair Pathway
The DSB repair pathway is involved in the repair of potentially lethal DNA doublestrand break lesions formed by broken strands of the DNA duplex. DSBs can be caused
by both exogenous agents such as ionizing radiation and cellular processes such as DNA
replication (Chapman et al., 2012). Flap structure-specific endonuclease 1 (FEN1),
Meiotic recombination 11 homolog A (MRE11A) and RAD50 homolog (RAD50) are
enzymes that function in the DSB repair pathway. FEN1 is a nuclease protein in the BER
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pathway and helps in the Polγ-catalyzed DNA synthesis process. Polymerase γ is
necessary for replication and repair as it is the only currently identified mitochondrial
DNA polymerase (Podlutsky et al., 2001a). MRE11A is a part of the Mre11 protein
complex which also includes Rad50 and Nbs1 proteins. The Mre11 protein complex has
multiple functions including initiation of cell cycle checkpoints and recognition and
repair of damaged DNA. Studies have shown a reduction in the expression of the Mre11
complex proteins in neurons of AD cortex compared to age-matched controls (Jacobsen
et al., 2004).
1.3.4. Mismatch Repair (MMR) Pathway
The MMR pathway repairs base-base and insertion/deletion mismatches that escape
proof-reading by DNA polymerase during replication and recombination. If left
unrepaired these mismatches can lead to mutations in DNA in subsequent replication
cycles which in turn can lead to phenotype changes and consequent dysfunction and
disease (Henneke et al., 2003; Hsieh and Yamane, 2008; Yamaguchi et al., 1989). EXO1
is an essential enzyme in the mismatch repair pathway and is involved in 5’-3’
exonuclease activity on dsDNA, 5’ flap endonuclease activity and weak RNaseH activity
(Balusu et al., 2007).
1.3.5. Other Genes Involved in DNA Repair
Other genes related to DNA repair studied in this project include Ataxia
telangiectasia mutated (ATM). ATM helps in regulation of the activity of molecules that
manage cell-cycle arrest and repair by initiating signal transduction pathways. ATM
deficiency may lead

to

radiation

sensitivity,
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germ

cell

degeneration,

mild

immunodeficiency, and an extreme sensitivity to developing T cell lymphomas (Strom et
al., 2011).
1.4. Additional Neurodegenerative Diseases
Besides AD, several other types of dementia leading to neurodegeneration exist
including vascular dementia, dementia with lewy bodies, frontotemporal dementia,
Creutzfeldt-Jakob disease, Parkinson’s disease, normal pressure hydrocephalus,
Huntington's disease and Wernicke-Korsakoff syndrome. In order to determine if the
changes seen in this study were AD-specific or were a common phenomenon of
dementia, tissue specimens were studied from diseased control subjects suffering from
dementia with lewy bodies (DLB) and frontotemporal dementia (FTD).
1.4.1. Dementia with Lewy Bodies
Dementia with Lewy bodies accounts for 10-25% of dementia cases making it the
second most common form of dementia in elderly populations after AD (Zaccai et al.,
2005). Clinically, DLB is difficult to diagnose as it shares clinical, neuropsychological
and pathological hallmarks with AD, vascular dementia and Parkinson’s disease. DLB
patients suffer from visual hallucinations, delusions, significant memory loss, impairment
in thinking and reasoning, REM sleep disorder and Parkisonian symptoms such as
hunched posture, rigid muscles and shuffled gait. The neuropathological hallmark for
DLB is the presence of spherical intracellular microscopic inclusions called Lewy bodies
in the midbrain and cerebral cortex. The primary structural component of Lewy bodies is
a protein called α-synuclein (Henchcliffe et al., 2011; Zaccai et al., 2005). Currently, the
clinical diagnosis for DLB are based on criteria described by the Consortium on DLB
criteria and includes the semi-quantitative evaluation of lesion density in the brainstem,
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basal

forebrain/limbic

regions

and

neocortical

regions,

alpha-synuclein

immunohistochemistry, REM sleep behavior disorder, severe neuroleptic sensitivity, and
decreased activity of striatal dopamine transporter (McKeith et al., 2005).
1.4.2. Frontotemporal Dementia (FTD)
Frontotemporal dementia is defined as a group of multiple neurodegenerative
diseases caused by progressive neurodegeneration in the frontal and temporal lobes. FTD
accounts for approximately 4-20% of all dementia cases with average age of onset being
in the 50’s or early 60’s. Patients with FTD can survive from 2-20 years with most
subjects surviving an average of 6-8 years. Occurrence of FTD is more common in men
than women at a ratio of 14:3 (Grossman, 2002; Ratnavalli et al., 2002). Symptoms of
FTD can be categorized into three different groups:
1.4.2.1. Behavioral Variant Frontotemporal Dementia (bvFTD)
Patients with bvFTD primarily show changes in personality and behavior. Clinically,
bvFTD patients suffer from disinhibition, apathy, loss of sympathy, compulsive
behaviors, hyperorality and a dysexecutive neuropsychological profile (Rascovsky et al.,
2011).
1.4.2.2. Primary Progressive Aphasia (PPA)
In PPA, language is impaired in the early stage of the disease followed by changes in
behavior in advanced stages. The two primary forms of PPA are semantic dementia and
progressive nonfluent aphasia (PNFA). Semantic dementia patients are characterized by
increasing decline of naming and word comprehension but retention of fluency in syntax
and phonology. People with PNFA suffer from impairments in speech articulation and
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reading and writing ability but preserve speech comprehension abilities (2010; Lambon
Ralph et al., 1999; Sobol et al., 1996).
1.4.2.3. FTD Movement Disorders (FTDMD)
Impairments in language, behavior and involuntary, automatic muscle functions are
characteristic of FTD movement disorders. Most prevalent forms of FTDMD include
corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). CBD is
characterized by shakiness, lack of coordination, muscle rigidity and spasms whereas
PSP patients show eye movement, walking and balance problems; neck and upper body
muscle stiffness and frequent falls (Keith-Rokosh and Ang, 2008; Mahapatra et al., 2004;
Scaravilli et al., 2005).
Clinical diagnosis of FTD is based on observation of behavioral changes, brain
imaging and neuropsychological tests. MRI images can help detect frontal/temporal
atrophy characteristic of FTD in the later stages. The similarity of symptoms between AD
and FTD makes the clinical diagnosis of FTD difficult. Pathologically FTD diagnosis is
based on immunohistochemical evaluation for Tau epitopes, PHF1 (PHD finger protein
1) and AT8 (paired helical filament tau), ubiquitin and α-synuclein in the middle frontal
gyrus

(MFG),

superior

temporal

gyri

(SMG),

parietal

lobe

(PL),

hippocampus/parahippocampal gyri (HPG), and the cingulated gyrus (CG) (Hutton et al.,
1998; Neumann et al., 2007; Rosen et al., 2002; Talbot et al., 1998).
1.5. Statements of Research Projects
1.5.1. Oxidative DNA Damage in Genes of Proteins Modified During AD
Although multiple studies demonstrate increased oxidative DNA damage in the
progression of AD (Gabbita et al., 1998; Lovell et al., 1999; Lovell and Markesbery,
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2007b; Markesbery and Lovell, 2006), the exact site of the oxidation in the human
genome remains unclear. We hypothesized that DNA oxidative damage is not an
arbitrary process but may be distinctively localized to specific genes. We further
hypothesize that the most highly oxidized genes are those coding for proteins whose
expression has shown to be altered in the brain of AD subjects. In order to test this
hypothesis, nDNA from NC, MCI, PCAD and LAD specimens were treated with
formamidopyrimidine glycosylase (fpg), a DNA repair enzyme that recognizes and
removes damaged bases including 8-oxoguanine, 8-oxoadenine, fapy-guanine, methyfapy-guanine, fapy-adenine, aflatoxin B1-fapy-guanine, 5-hydroxy-cytosine and 5hydroxy-uracil. Formamidopyrimidine glycosylase has both N-glycosylase (release of
damaged purines from dsDNA creating an apurinic (AP) site) and AP-lyase (cleavage of
AP site) activities leading to a single-nucleotide gap flanked by phosphate termini in
damaged DNA (Du et al., 2009). The percent oxidative damage in different amplicons of
genes coding for proteins shown to be altered in the progression of AD were then
quantified using quantitative/real-time polymerase chain reaction (qPCR/ RT-PCR). To
understand the utilization of qPCR in this study, both traditional PCR and qPCR are
discussed in the following section. Table 1.1 lists several genes for which alterations in
proteins are observed in AD. This study focused on the three isoforms of the voltage
dependent anion channel proteins, VDAC1, 2 and 3. VDACs were the ideal candidate for
this study as the three forms differ in abundance, size and activity, and are altered
differentially in the AD brain. Lovell et al. found a significant elevation of VDAC1
levels, no significant change in VDAC2 levels and a trend towards significant increase of
VDAC3 levels in Aβ-treated primary rat cortical neuron cultures (Lovell et al., 2005). To
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test the assumption oxidation of the coding sequence of a protein leads to differential
protein levels and activity, we designed an experiment using the protein IGF2 (insulin
like growth factor-II). IGF2 was selected for this experiment because it has one of the
smallest coding sequences (only 202 bp in length) and well characterized activity assays.
Progressively increasing amounts of 8-oxoguanine were incorporated into the IGF2
coding sequence and the DNA thus obtained subjected to in vitro transcription and
translation using a cell free system to produce the IGF2 protein. The protein levels and
activity in these samples was quantified and compared to a positive control sample
containing no oxo-guanine.
1.5.1.1. Polymerase Chain Reaction
Polymerase chain reaction (PCR) is a biochemical technique conceived by Kary
Mullis and colleagues in 1985 for exponentially amplifying short DNA segments (100600 bases). Automation of PCR following the discovery and isolation of thermo-stable
DNA polymerase (Taq polymerase) from the bacterium Thermus aquaticus has led to its
application in multiple facets of biology and chemistry. The reaction components of a
traditional PCR reaction include target DNA, forward and reverse primers, DNA
polymerase, deoxynucleotide triphosphates (dNTPs), MgCl2, PCR reaction buffer and
water. The PCR reaction buffer provides an optimal pH and monovalent salt environment
and water acts as an interaction medium for the other reaction components of the PCR
reaction. Magnesium cations required as cofactors for the DNA polymerase enzymes are
provided by MgCl2. Individual DNA bases are supplied by the dNTPs to DNA
polymerases for formation of new DNA strands during a PCR reaction. The β and γ
phosphates of the dNTPs also fulfill the energy requirements of the PCR reaction. Target
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DNA provides the template for amplification by DNA polymerases. Ideally, template
DNA should be uncontaminated by any other DNA/RNA source. Specific thermostable
DNA polymerases including Taq polymerase (source: Thermus aquaticus) , Tth
polymerase (source: Thermus thermophilus), Tfl polymerase (source: Thermus flavus),
Pfu polymerase (source: Pyrococcus furiosus) Tli polymerase (source: Thermus litoralis)
and Pyrococcus species GB-D may be used in PCR reactions dependent on specific
application. The DNA polymerase enzyme for a PCR reaction is selected based on three
factors, (1) processivity (rate at which the polymerase produces a complementary copy of
the template), fidelity (accuracy of complementary copy formation) and persistence
(stability of enzyme at high temperature). Taq polymerase, the most commonly used
enzyme in PCR, has a procesivity of 50-60 nucleotides per second at 72

C, an error rate

of 285 x 10-6 errors per template nucleotide and a half-life of 1.5 hours at 95

C. Taq

polymerases have 5’→3’ nuclease activity but lack 3’→5’ proof reading ability leading
to the incorporation of a single 3’ adenosine nucleotide on both strands of every
amplicon. Primers are short oligonucleotide sequences designed to be complementary to
the target DNA necessary for new DNA strand synthesis and are usually added in excess
amounts in a PCR reaction. For maximum efficiency of a PCR reaction, primers should
be at least 20 nucleotides in length with PCR reaction compatible melting temperatures
and the forward and reverse primers should not form primer-dimer bands. In
conventional PCR, PCR products are visualized using ethidium bromide on an agarose
gel and analyzed using radio-imaging or other densitometric methods.
Typically a PCR reaction is characterized by three steps shown in Figure 1.5:
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a) Denaturation in which the double stranded target DNA is denatured by heating to 9495 oC to produce single stranded DNA strands that act as templates for new DNA strand
synthesis.
b) Annealing in which DNA primers anneal to the complementary single stranded DNA
in preparation for DNA synthesis by DNA polymerases. This annealing process requires
cooling to the primer annealing temperature which is determined by the melting
temperatures of the primers. The temperature at which 50% of a DNA duplex dissociates
to become single stranded DNA is called its melting temperature (Tm). Tm’s are
dependent on pH, ionic strength and base composition of DNA. Primer annealing
temperatures are typically 2 oC lower than the lowest primer Tm.
c) Elongation in which new DNA is synthesized by addition of dNTPs onto the primers
by DNA polymerase in the 5’→ 3’ direction from the primer. The release of
pyrophosphate on addition of dNTPs to the growing DNA strand provides the energy
needed for the polymerase to appropriate and add the next complementary base.
Polymerization usually occurs at a temperature of 72 oC, the optimal temperature for Taq
polymerase but the polymerization temperature used can vary based on length of product,
number of cycles and usage of other DNA polymerases for polymerization.
These three steps are repeated for a defined number of cycles depending on the output
required. A PCR reaction with 25-40 cycles is the usual norm.
A PCR reaction theoretically doubles the amount of target DNA after each reaction
cycle. For example, a PCR reaction with 25 cycles should produce 225 or more than 33
million copies of the amplicon for each double stranded target DNA molecule present.
This can be represented by the exponential curve shown in Figure 1.6a. Experimentallly
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PCR amplification typically resembles Figure 1.6b and is composed of three separate
sequential phases:
a)

Exponential phase: In the initial exponential phase DNA polymerase works at near

optimum capacity leading to almost exact doubling in the amount of product after each
cycle. This phase closely resembles the theoretical expectation of PCR amplicon
production and has high specificity and precision.
b)

Linear phase: After a time, reaction components are consumed at different rates, the

amplicon production slows down and the PCR reaction enters a quasi-linear phase.
Amplification of the target is highly variable in this phase.
c)

Plateau phase: This is the final phase of the PCR reaction which is traditionally

detected by gels (end-point detection). In this phase, amplicon production is negligible.
Consumption of reaction components, reduction in DNA polymerase activity due to heat,
limited concentrations and increasing pyrophosphate concentration, reannealing of
products at higher concentrations and risk of degradation of products over time due to
Taq polymerase 5’-3’ exonuclease activity are some of the factors contributing to the
plateau phase in later PCR cycles (Garrett and Grisham, 2010; Kainz, 2000; Lehninger et
al., 2005; Peake, 1989; Rose, 1991; Saiki et al., 1985)
Figure 1.7 shows the PCR amplification of three replicate samples with the same
amount of DNA at the start of the reaction. After PCR, these samples show different
quantities instead of identical quantities at the plateau phase. On the other hand, the
replicate samples have identical graphs in the exponential phase. Figure 1.8 shows the
PCR amplification curve for a 7-fold dilution series. Although the exponential phase
distinctively shows a difference between the samples, the difference in DNA quantities is
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not very perceptible in the plateau phase. Hence, it seems more accurate to measure the
amount of DNA in the exponential phase rather in the plateau phase as has been done
traditionally.
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Figure 1.6: PCR amplification (A) theoretical and (B) experimental
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Figure 1.7: PCR amplification of 3 replicate samples
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Figure 1.8 : PCR amplification of a 7-fold dilution series

1.5.1.2. Real Time Quantitative PCR (qPCR)
Due to the limitations of end-point detection in traditional PCR, the amount of
product obtained is not always fully comparable to the amount of input DNA. Thus this
method can at best be characterized as semi-quantitative/qualitative. Traditional PCR also
has the disadvantages of low sensitivity and resolution, non-quantitative staining by
ethidium bromide, additional post PCR processing steps and a narrow dynamic range (<
2 logs). In contrast, real time quantitative PCR quantifies amplification in the exponential
phase of the PCR reaction thus eliminating the inconsistency associated with end-point
detection in traditional PCR and therefore providing the accurate amount of starting
target sample. Real time quantitative PCR (qPCR) can detect upto a two-fold change in
concentration compared to agarose gel analysis which can only detect a 10-fold change in
concentration. qPCR also uses highly sensitive fluorescent dyes such as SYBR green for
detection instead of a low fluorescence dye like ethidium bromide. qPCR also has the
advantages of wide dynamic range (> 107 fold) and an absence of post PCR processing.
Since the first reported qPCR procedure by Higuchi et al in 1993 (Higuchi et al.,
1993), qPCR has found

use in multiple biochemical applications including gene

expression studies, quantification of DNA copy number in genomic or viral DNA,
quantitation of cytokine levels, microarrays and allelic discrimination assays. 5’ nuclease
assays using Taqman probes, molecular beacons and SYBR Green fluorescent dyes are
the most common chemistries used in qPCR (Bustin et al., 2005; Espy et al., 2006;
Mackay et al., 2002; VanGuilder et al., 2008) .
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1.5.1.3. qPCR Data Analysis
The increase in fluorescence during a PCR reaction is detected in real time using any
of the different probe chemistries used in qPCR. Some of the important terms used in
data analysis are briefly described below (Figure 1.9) (Arya et al., 2005):
a) Baseline: The baseline for a qPCR reaction is usually between cycles 1 and 15 and is
defined as the number of qPCR cycles that lead to a fluorescence signal below the limits
of detection of the qPCR instrument.
b) ΔRn: ΔRn is the difference between the fluorescence signal of the product at each time
point and the fluorescence signal of the baseline. Amplification curves in a qPCR
reaction are produced by plotting ΔRn vs cycle number.
c) Threshold: An arbitrary threshold, measured as approximately ten times the standard
deviation of the average fluorescent signal of the baseline is usually chosen by the qPCR
software. The threshold is in the region of exponential amplification and provides a
minimal detection level for the qPCR reaction. It can be changed manually to include the
amplification curves of multiple reactions.
d) Ct (Threshold cycle): Ct is the PCR cycle number at which a detectable, statistically
significant fluorescence signal is observed. The higher the initial concentration of
template DNA in the qPCR reaction, the lower the Ct value. The Ct value is always
observed in the exponential phase of DNA amplification and is the basis for data analysis
methods in qPCR.
The two different methods used for quantification and analysis of data obtained in qPCR:
absolute quantification/ standard Curve method and the relative quantification/
comparative Ct method which are briefly described below.
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Figure 1.9. Description of terms used in qPCR data analysis
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1.5.1.3.1. Absolute Quantification/ Standard Curve Method
In this method, a standard curve is obtained by plotting the log of initial DNA
concentration for a set of known standards (five or ten fold dilution series) versus Ct and
should be a straight line for an efficient qPCR reaction (Higuchi et al., 1993). The amount
of DNA in unknown samples is then determined by measuring their Ct values and
comparing these Ct values with the standard curve. Purified plasmid DNA, synthetic
ssDNA or any cDNA/DNA sample expressing the target gene can be used to generate the
standard curve. This method is used in experiments requiring the absolute quantitation of
sample (Arya et al., 2005; Schmittgen and Livak, 2008).
1.5.1.3.2. Relative Quantification/ Comparative Ct/ 2-ΔΔCt Method
In the comparative Ct method, quantification is carried out by comparing the Ct
value of the sample of interest to the Ct value of an internal control or some calibrator
such as a non-treated sample. Appropriate housekeeping genes (HKGs) are used to
normalize the Ct values of both the sample of interest and the internal control.
Housekeeping genes commonly used for qPCR include glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), β-actin, 28S or 18S ribosomal RNA, β2-microglobulin,
hypoxanthine-guanine, cyclophilin or phophoribosyl transferase (HPRT) (Arya et al.,
2005; Derveaux et al., 2010). In order to use the comparative method, it is assumed that
PCR reaction efficiency is 1 and that both the sample of interest and internal control have
similar PCR efficiency. The amount of target is calculated by the formula 2-ΔΔCt (Livak
and Schmittgen, 2001; Schmittgen and Livak, 2008) where
ΔΔCt = ΔCt,sample − ΔCt,control
ΔCt,sample = Ct,sample − Ct,HKG

48

ΔCt,control = Ct,control − Ct,HKG
1.5.1.4. Voltage Dependent Anion Channels (VDACs)
Pore-forming VDACs, also known as mitochondrial porins, are found in the
mitochondrial outer membrane and brain postsynaptic membranes and are ion channels
that facilitate transport of small hydrophilic solutes including ATP, ADP, Pi, Ca2+, K+
and Na+ from the cytosol to mitochondrial sites of utilization or vice versa. In addition,
VDAC along with adenine nucleotide translocase and cyclophilin-D form the
mitochondrial permeability transition pore (PTP). Three different isoforms of the VDAC
protein: VDAC1, VDAC2 and VDAC3 have been observed in humans. Although the
three isoforms are sequentially homologous and are expressed in most tissues, they differ
in function and abundance in the human body. For example, VDAC3 has diminished
pore-forming ability compared to VDAC1 and VDAC2. VDACs form ion channels
between the mitochondrial outer and inner membranes and have been implicated in the
regulation of apoptosis and membrane potential, and ATP production. Mitochondrial
function is considered to be regulated by the voltage dependent closure/opening of
VDACs. Studies show that VDAC forms a single 2.5-3 nm wide pore which shows a
slight anion-selectivity in its open state and slight cation- selectivity in its partially closed
state. VDACs are open at low voltages (≈ ±10 mV) and closed at higher voltages (over
±30 mV). In addition, VDACs act as coordination sites for multiple ATP using cytosolic
enzymes including hexokinase, glucokinase, glycerol kinase and mitochondrial creatine
kinase. Multiple studies (Cuadrado-Tejedor et al., 2011; Lovell et al., 2005; Yoo et al.,
2001) have shown changes in VDAC proteins in the brain of patients with Alzheimer’s
disease. Lovell et al. found a significant elevation of VDAC1 levels, no significant
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change in VDAC2 levels and a trend towards significant increase of VDAC3 levels in
Aβ-treated primary rat cortical neuron cultures (Lovell et al., 2005). Yoo et al. reported a
significant decrease in VDAC1 levels in thalamus and frontal and temporal cortex and
significant elevation of VDAC2 levels in temporal cortex of AD subjects (Yoo et al.,
2001). A recent study by Cuadrado-Tejedor et al. showed an overexpression of VDAC1
in the brain of AD patients (Cuadrado-Tejedor et al., 2011).
1.5.2. Changes in DNA Repair Enzymes of BER Pathway in AD Subjects
Increased oxidative DNA damage seen during the progression of AD could be due to
either an increase in formation of oxidized DNA lesions or due to impairments in DNA
repair mechanisms or both. Previous studies suggest DNA repair pathways may be
diminished in the progression of AD and may contribute to increased accumulation of
markers of DNA oxidation (Bohr, 2002; Dianov et al., 2001; Weissman et al., 2007). In
this study, we hypothesized that the BER pathway has diminished repair capacity
throughout the progression of AD leading to increased oxidative DNA damage seen
during AD. To test this hypothesis, custom PCR arrays containing genes for 12 DNA
repair enzymes, 2 housekeeping genes (Beta actin (ACTB) and Glyceraldehyde-3phosphate dehydrogenase (GAPDH)), and negative and positive PCR controls, and qPCR
were used to quantify expression levels for DNA repair enzymes relative to the
pathogenesis of AD. To confirm PCR results, enzyme activities were assessed using gel
shift assays and radiolabeled/fluorescent oligonucleotides and protein levels were
quantified using Western blot analysis and antibodies specific for each protein.
For both projects, tissue specimens were analyzed from normal control (NC)
subjects and subjects throughout the progression of AD including those with preclinical
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AD (PCAD), mild cognitive impairment (MCI), late-onset AD (LAD), and diseased
control (DC) including frontotemporal dementia (FTD) and dementia with Lewy bodies
(DLB) subjects. Both projects analyzed specimens from a vulnerable brain region
(superior and middle temporal gyri (SMTG) and a non-vulnerable region (cerebellum
(CER)).
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Table 1.1. List of potential genes studied in Project 1

#

Name used Gene
in
experiment

1

VDAC1

Voltage dependent anion-selective channel protein 1

2

VDAC2

Voltage dependent anion-selective channel protein 2

3

VDAC3

Voltage dependent anion-selective channel protein 3
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CHAPTER TWO: MATERIALS AND METHODS
2.1. Materials
2.1.1. Brain Specimen Sampling
Brain tissue specimens of superior and middle temporal gyri (SMTG) and
cerebellum (CER) of NC, MCI, PCAD, LAD and DC subjects were collected from short
postmortem interval (PMI) autopsies and stored at -80 ◦C until used for analysis. All
subjects were followed longitudinally at the University of Kentucky Alzheimer’s Disease
Center Clinic (UK-ADC) and had annual neuropsychological testing and physical and
neurological exams. Results of neuropsychological testing for NC subjects were in the
normal range. MCI subjects were normal upon enrollment into the study cohort but
developed MCI during follow up. MCI subjects were diagnosed based on clinical criteria
described by Petersen et al. which include: (a) memory complaints (b) objective memory
impairment for age and education (c) normal general cognitive function (d) intact
activities of daily living and (e) the subject not meeting criteria for dementia (DeCarli,
2003; Maynard et al., 2010; Petersen et al., 2009; Petersen et al., 1999).
Histopathologically, MCI subjects showed a significant increase in neuritic plaques in
neocortical regions and a significant increase in neurofibrillary tangles in the
hippocampus, entorhinal cortex and amygdala, compared to NC subjects (Markesbery et
al., 2006). Braak staging scores for MCI subjects were in the range of III-IV. Preclinical
AD (PCAD) subjects were diagnosed based on the tentative criteria set by the UK-ADC
which includes (a) pronounced AD pathology with Braak scores of III-V and (b)
antemortem psychometric tests in the normal range when corrected for age and education
(Schmitt et al., 2000). Subjects with Braak scores of VI who met both standard clinical
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and histopathological criteria for probable AD were diagnosed with LAD (Bradley et al.,
2010; Schmitt et al., 2000).
Samples from subjects with dementia with Lewy bodies (DLB) and frontotemporal
dementia (FTD) were analyzed as diseased control specimens. DLB patients showed
antemortem diagnostic features including visuospatial problems worse than memory
problems, executive dysfunction, sleep disturbance, visual hallucinations, facial masking
and decreased dopamine transporter in the absence of systemic or neurologic disorders.
Pathologically, DLB was characterized by the presence of ubiquitin and α-synuclein
positive Lewy bodies (LB) and α-synuclein positive Lewy neurites (LN) in the limbic and
temporal regions of the brain. In addition, some DLB brain specimens may have ADtype pathology including neurofibrillary tangles and diffuse/ neuritic plaques (Ferman
and Boeve, 2007; Geldmacher, 2004)
Frontotemporal dementia describes a group of progressive neurodegenerative
diseases with diagnostic features including changes in personal and social behavior,
akinesia, progressive aphasia, labile blood pressure and a variety of other exclusionary
features. Pathological changes include degeneration of frontal and/or anterior temporal
lobe and basal ganglia, microvacuolation, swollen cortical neurons, neuron loss and loss
of pigmentation in the substantria nigra (Graff-Radford and Woodruff, 2007; Grossman,
2002).
All subjects had neuropathological assessment of multiple sections of neocortex,
hippocampus, entorhinal cortex, amygdala, basal ganglia, nucleus basalis of Meynert,
midbrain, pons, medulla and cerebellum by the modified Bielschowsky stain,
hemotoxylin-eosin stain and Aβ, and α-synuclein immunostains. Braak staging scores
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were determined using the Gallyas stain on sections of the hippocampus, entorhinal
cortex and amygdala and the Bielschowsky stain on neocortex.
The subject demographics are shown in Table 2.1. Age, and post-mortem intervals
are reported as mean ± SEM (Table 2.1) and were compared using ANOVA. Braak
staging scores are listed as median [range] values and were compared using the Mann
Whitney U test.
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Table 2.1. Subject Demographics
PMI
Age

Braak

(Mean ± SEM)

(Median)

Score
(Mean

± Sex

SEM)
NC (N = 15)

86.3 ± 1.4

I

2.8 ± 0.2

4M : 11W

MCI (N = 7)

91.0 ± 1.9*

III*

2.6 ± 0.2

2M : 5W

PCAD (N = 13)

85.7 ± 1.8

IV*

2.8 ± 0.2

3M : 10W

LAD (N = 14)

81.4 ± 1.4

VI*

3.6 ± 0.4

6M : 8W

DC (N = 12)

68.9 ± 4.8*

II*

3.5 ± 0.4

7M : 5W
* P < 0.05
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2.1.2. Antibodies
Polyclonal rabbit anti-OGG1 was obtained from Novus Biologicals (Littleton, CO,
USA). Polyclonal rabbit anti-Ref1, polyclonal rabbit anti-XRCC1, polyclonal rabbit antiPOLB, polyclonal rabbit anti-PARP1, polyclonal rabbit anti-UDG and polyclonal rabbit
anti-FEN1 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Methods
2.2.1 Isolation of Nuclear DNA
For Project 1 (Oxidative DNA damage in genes of proteins modified during AD),
two separate methods of DNA isolation were tested to obtain the method with least
amount of artifactual oxidation of DNA during isolation. The subject demographics for
the study are shown in Table 2.1.
a) Genomic DNA was isolated from brain tissues using a DNeasy Tissue Kit per
manufacturer’s instructions (Qiagen, Valencia, CA). Briefly, ~ 25 mg brain tissue was
lysed by incubating overnight at 56 oC with proteinase K and lysis buffer. After lysis, AL
buffer (proprietary mix containing guanidine hydrochloride) and ethanol were added to
the sample mixture and the mixture was pipetted into a DNeasy Mini spin column and
centrifuged. The flow-through was discarded. The sample in the DNeasy Mini spin
column was washed with wash buffers (proprietary mix containing guanidine
hydrochloride and ethanol) and genomic DNA eluted using ddH2O.

Subsequent to

elution with ddH2O, purified DNA was stored at −80 °C.
b) Phenol Extraction Method: Total genomic DNA was isolated from brain tissues using
a previously published procedure (Mecocci et al., 1993; Sims and Anderson, 2008; Wang
et al., 2005). A glass Dounce homogenizer was used to homogenize brain tissue
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specimens in cold isolation buffer (0.3 M sucrose, 10 mM Tris-HCl, 1 mM K2EDTA, pH
7.4) (10% tissue wet wt/vol). The homogenate was centrifuged at 1,300 x g at 4°C for 3
minutes. The pellet obtained was resuspended in isolation buffer and centrifuged again at
1,300 x g at 4 °C for 3 minutes. The resulting pellet was used for nuclear DNA (nDNA)
isolation by the phenol extraction method. The pellet was resuspended in digestion buffer
(0.5% sodium dodecyl sulfate, 0.05 M Tris-HCl, 0.1 M Na2EDTA) with proteinase K
(0.5 mg/ml) and incubated overnight in a water bath at 56°C. After overnight incubation,
160 µL of 5 M NaCl per 10 mL solution was added to the mixture. This was followed by
extraction with buffer-saturated phenol containing 5.5 mM 8-hydroxyquinoline (to limit
artifactual DNA oxidation) three times and three times with chloroform/isoamyl alcohol
(24:1). 800 µL of 5 M NaCl per 10 mL was added to the resulting clear extract along
with an equal volume of chilled absolute ethanol and left overnight at -20°C to precipitate
nDNA. Subsequently, the DNA pellet was centrifuged, washed three times with 60%
ethanol and air-dried. The pellet was then dissolved in nuclease-free water. The
concentration and purity of DNA samples at 260 and 280 nm was measured using a
ND1000 Nanodrop Spectrophotometer (Thermoscientific, Wilmington, DE).
2.2.2. Polymerase Chain Reaction (PCR)
PCR reactions were performed with genomic DNA initially to verify oxidative
damage in specific genes with a range of primers designed for each gene (listed in Table
2.2). PCR reactions were also used to validate the primers obtained for RT-PCR (listed in
Table 4). A PCR reaction mixture contained 250 ng genomic DNA, 1× Thermoscientific
PCR Master Mix and 1 μM primer mix (forward and reverse) in a total volume of 25 µL.
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A 1.2% low-melt agarose gel containing ethidium bromide was used to separate the PCR
products (Wang et al., 2005).

59

Table 2.2. Primers for PCR
Gene

VDAC1

VDAC1

VDAC1

VDAC2

VDAC2

VDAC2

DNA bp

Bp

location

length

134-913

780

134-505

438-913

193-546

545-749

726-1024

1024-

372

Tm

Primer sequence

(oC)
5’-AATCTGCCAGGGATGTCTTCACCA-3’

60.3

Forward

5’-CACCAGCATTGACGTTCTTGCCAT-3’

60.3

Reverse

5’-AATCTGCCAGGGATGTCTTCACCA-3’

60.3

Forward

5’-GCCCAGCAATGTCGAAATCCATGT-3’

60.2

Reverse

5’-AATCAAGACAGGGTACAAGCGGGA-3’

60.2

Forward

5’-CACCAGCATTGACGTTCTTGCCAT-3’

60.3

Reverse

5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’

60.2

Forward

5’-CAAGCCAGCCCTCATAACCAAAGA-3’

59.4

Reverse

5’-TGCTGGCTACCAGATGACCTTTGA-3’

60.2

Forward

5’-ACGAGTGCAGTTGGTACCTGATGT-3’

60.2

Reverse

5’-ACATCAGGTACCAACTGCACTCGT-3’

60.2

Forward

5’-CCTGCTGCTGGTCACAATGGAAAT-3’

60.0

Reverse

5’-GCTTTTTTCCCCCAAGAAGATGAT-3’

55.9

Forward

5’-TTGTCATGTTCTGGGATACCAAAA-3’

54.7

Reverse

5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’

60.2

Forward

5’-TGGTACCTGATGTCCAAGCAAGGT-3’

60.2

Reverse

5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’

60.2

Forward

5’-ACGAGTGCAGTTGGTACCTGATGT-3’

60.2

Reverse

5’-CAAAGTCTTGCAGTGGCGTGGAAT-3’

60.2

Forward

5’-CCTGCTGCTGGTCACAATGGAAAT-3’

60

Reverse

476

354

205

299

381

VDAC2
1404

VDAC2

VDAC2

VDAC2

193-738

193-749

193-1021

546

557

829
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2.2.3. Oxidative DNA Damage
Real time PCR/ quantitative PCR was used to determine the level of oxidative
damage in the DNA sequences of various genes. The range of primers designed for each
gene, are listed in Table 2.3. Briefly, 250 ng of total genomic DNA was incubated with 8
units of formamidopyrimidine glycosylase (fpg) and 100 μg/ml of BSA at 37°C for 12 h.
The fpg enzyme was inactivated after 12 h by incubation at 60°C for 10 min. Real time/
quantitative PCR was carried out with an aliquot of the reaction mixture on an ABI 7000
Sequence Detection System using TaqMan 2x PCR Master Mix (Applied Biosystems,
Carlsbad, CA) and SYBR Green for detection. The RT-PCR reaction mixture contained
1× TaqMan PCR Master Mix, 4 μM primer mix (forward and reverse), SYBR Green,
ROX reference dye and template genomic DNA. The absolute concentrations of intact
DNA in the template were calculated using a standard curve derived from 5-fold serial
dilutions of genomic DNA from NC subjects. The data presented show the average of
triplicates from RT-PCR. Oxidative damage was calculated as

% Oxidative damage =

(intact DNA in nontreated aliquot - intact
DNA in fpg treated aliquot)
intact DNA in nontreated aliquot

RT-PCR reaction mixtures without template DNA served as negative controls in order to
monitor nonspecific amplification. PCR products were verified by melting curves (Du et
al., 2009).
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Table 2.3. Primers for RT-PCR
Table 2.3.1. VDAC1 primers
Gene

VDAC1A

VDAC1B

VDAC1C

VDAC1D

VDAC1E

VDAC1G

VDAC1H

DNA bp

bp

location

length

438-613

176

482-689

666-913

695-896

722-913

914-1173

1174-

208

248

202

192

260

238

1411
VDAC1I

13981594

196

Primer sequence

Tm
(oC)

5’-AATCAAGACAGGGTACAAGCGGGA-3’

60.2

Forward

5’-CAACTGCAAAGTTGCTCTGGGTCA-3’

60.0

Reverse

5’-ACATGGATTTCGACATTGCTGGGC-3’

60.2

Forward

5’-TTCTGGTAAATGGAGCCGCCAAAC-3’

59.9

Reverse

5’-GTTTGGCGGCTCCATTTACCAGAA-3’

59.9

Forward

5’-CACCAGCATTGACGTTCTTGCCAT-3’

60.3

Reverse

5’-ACAAGAAGTTGGAGACCGCTGTCA-3’

60.4

Forward

5’-TTGCCATCCAGAAGAGCTGACAGT-3’

60.4

Reverse

5’-TTGCCTGGACAGCAGGAAACAGTA-3’

60.5

Forward

5’-CACCAGCATTGACGTTCTTGCCAT-3’

60.3

Reverse

5’-GCCACAAGCTTGGTCTAGGACTGG-3’

61.6

Forward

5’-AAGTTCTCCCCGAGTCTACCACTG-3’

59.8

Reverse

5’-GAGAACTTGGTGGCCCCTTTGAGA-3’

61.0

Forward

5’-GGGGTGGGAACAGGTCATGAAGAT-3’

60.8

Reverse

5’-CCTGTTCCCACCCCAGTTCATCAT-3’

61.0

Forward

5’-GCTGGAGCTCCTGGAAGCTATTTC-3’

59.6

Reverse
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Table 2.3.2. VDAC2 primers
Gene

VDAC2A

VDAC2B

VDAC2C

VDAC2D

VDAC2E

VDAC2G

VDAC2H

DNA bp bp
location

length

24-213

190

167-354

331-538

522-738

726-956

948-1152

11261310

188

208

217

231

205

185

Primer sequence

Tm
(oC)

5’-GCGAAGTGAAGGAGACACCGTTCC -3’

61.7

Forward

5’-CCACGCCACTGCAAGACTTTGTTT -3’

60.6

Reverse

5’-TGGGTTGGTGAAACTGGATGTGAA -3’

58.9

Forward

5’-TTGCGATTTCTGTTCCCAGAGTGT -3’

58.8

Reverse

5’-ACACTCTGGGAACAGAAATCGCAA -3’

58.8

Forward

5’-CCCTCATAACCAAAGACAGCTGAACC

59.4

Reverse

5’-GTCTTTGGTTATGAGGGCTGGCTT -3’

59.4

Forward

5’-TGGTACCTGATGTCCAAGCAAGGT -3’

60.2

Reverse

5’-ACATCAGGTACCAACTGCACTCGT -3’

60.2

Forward

5’-TCAGCTGGATTAAGCCTCCAACTC -3’

58.7

Reverse

5’-TCCAGCTGAAAGAAACCTTTGGGA -3’

58.7

Forward

5’-GCAGGACTGCAGCATTGGTAACTA -3’

59.3

Reverse

5’-ATCTAGTTACCAATGCTGCAGTCC -3’

56.8

Forward

5’-CCACTGATCCATCTCATTCAATGGT -3’

56.9

Reverse
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Table 2.3.3: VDAC3 primers
Gene

VDAC3A

VDAC3B

VDAC3C

VDAC3D

VDAC3E

DNA bp bp
location

length

248-447

200

367-651

540-735

627-865

718-932

285

196

239

215

Primer sequence

Tm
(oC)

5’-AGGGAAAGCATCAGGCAACCTAGA-3’

60.1

Forward

5’-AGGAGGCCTTCAATTTCCCACTCT-3’

60.2

Reverse

5’-TGGCTGAAGGGTTGAAACTGACTC-3’

59.2

Forward

5’-GTTCTCATGTGTGTGCAGATGGAA-3’

57.5

Reverse

5’-TGGCTTGCTGGCTATCAGATGAGT-3’

60.3

Forward

5’-TCCCAGCTGTCCAAGCAAGGTTTA-3’

60.6

Reverse

5’-TTCCAGCTGCACACACATGTGAAC-3’

60.2

Forward

5’-ATTTGACTCCTGGTCGAAGGGTCT-3’

59.7

Reverse

5’-TTGCTTGGACAGCTGGGAGTAACA-3’

60.5

Forward

5’-AAATCCCAAGCCAACCTTGTGACC-3’

60.1

Reverse
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2.2.4. Oxoguanine Incorporation into IGF2 Gene Sequence
PCR reactions were performed with genomic DNA with primers designed
specifically for IGF2. PCR reaction mixtures contained 100 ng genomic DNA, 10mM
dATP, 10mM dCTP, 10mM dTTP, 10mM (deoxyguanine/8-oxoguanine in varying
ratios), 10X PCR reaction buffer, Taq polymerase, 25 mM MgCl2 and 10 μM primer mix
(forward and reverse) in a total volume of 25 µL. A 1.2% low-melt agarose gel
containing ethidium bromide was used to separate the PCR products (Wang et al., 2005).
The PCR product band was excised from the agarose gel and purified DNA was obtained
using a gel extraction kit and a DNA clean-up and concentration kit per manufacturer’s
instructions (Zymo Research, Irvine, CA).
2.2.5. In vitro Transcription
IGF2 DNA with 8-OHG was transcribed to RNA in vitro using a Megascript kit per
manufacturer’s instructions (Life Technologies, Grand Island, NY). Briefly, 100-500 ng
of template DNA was incubated with dNTPs (2 μl each of ATP, CTP, GTP and UTP), 2
μl enzyme mix, 2 μl of 10X reaction buffer and water at 37 °C for 16 hours. The reaction
mixture was then incubated at 37 °C for 15 minutes with 1 μl DNase to remove template
DNA. The RNA transcript was purified using the phenol:chloroform extraction and
isopropanol precipitation. RNA transcript was diluted by addition of 115 μl of water and
15 μl ammonium acetate solution and extracted with an equal volume of phenol and then
with an equal volume of chloroform. RNA was then precipitated with an equal volume of
isopropanol overnight. The pellet removed after centrifugation was resuspended in
nuclease-free water and sample was stored at −20°C.
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2.2.6. In vitro Translation
IGF2 protein was synthesized in vitro using a Retic Lysate IVT kit per
manufacturer’s instructions (Life Technologies, Grand Island, NY). Briefly, 100-750 ng
in vitro transcribed RNA was incubated in a reaction mixture containing 20X translation
mix (-Met), 50 μl L-Met, 17 μl retic lysate and nuclease-free water at 30 °C for 90
minutes. The mixture was then incubated with 2.5 μl of 1 mg/ml RNase at 30 °C for 10
minutes. Subsequently, the reaction mixture was placed on ice for 5 minutes to quench all
reactions and stored at −20 °C.
2.2.7. IGF2 Activity Assay
IGF2 activity assays were as previously described (Gicquel et al., 2004; Spicer et al.,
1994). Briefly, IGF2 was radioiodinated in a 20 μl reaction mixture containing 0.3M
PBS, 1mCi Na-125I and 1.6 μg chloramine-T at 25 °C for 30 s. 6 μg of sodium
metabisulfite was added to quench the reaction. Iodinated IGF2 specimens were
incubated with 150 μl plasma samples in a reaction mixture containing 25 mM Hepes (ph
7.4), 0.1% BSA and 0.1% Triton X-100 overnight at 4 °C. IGF2 binding complex pellets
were separated by precipitation with 4% gammaglobulin and 18% w/v PEG 6K, and
subsequent centrifugation. The pellet was counted in a scintillation counter. Blanks
containing only iodinated IGF2 and no plasma were run for each sample set.
2.2.8. RNA Isolation and cDNA Synthesis
a) RNA isolation: Total RNA was isolated from tissue specimens using an RNeasy
Tissue Kit per manufacturer’s instructions (Qiagen, Valencia, CA). Briefly, ~ 20 mg of
brain tissue was homogenized in RLT buffer (proprietary mix containing guanidine
thiocyanate and β-mercaptoethanol). Ethanol (one volume) was added to the
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homogenized sample and the reaction mixture was transferred to an RNeasy Mini spin
column. The spin column was subsequently washed with multiple washing buffers and
total RNA eluted using RNAse-free H2O. Following elution with RNAse free H2O,
purified RNA was stored at −80 °C or used directly for cDNA synthesis.
b) cDNA synthesis: RNA samples were converted into cDNA using the RT2 First Strand
Kit per manufacturer’s instructions (SABiosciences, Frederick, MD). Briefly, 75-100 ng
of RNA were incubated with genomic DNA elimination buffer at 42°C for 5 minutes in
order to eliminate genomic DNA contamination. The reaction mixture was then mixed
with a reverse transcription cocktail provided in the kit and incubated at 42 °C for exactly
15 minutes. The reverse transcription reaction was quenched by heating the mixture at
95°C for 5 minutes. The sample was diluted with RNAse free H2O and stored at −20°C
overnight.
2.2.9. Quantitative Polymerase Chain Reaction with custom PCR arrays
Quantitative PCR was carried out on an ABI 7000 Sequence Detection System using
2x SABiosciences RT2 qPCR Master Mix. The qPCR reaction mixture contained 2x
SABiosciences RT2 qPCR Master Mix, and 250 ng of cDNA. 25 μl of the sample
experimental cocktail was added to each well of 96-well Custom PCR arrays and placed
in the real-time thermal cycler. The thermal cycler was run according to the real-time
thermal cycler program recommended by the manufacturer (SABiosciences, Frederick,
MD). The Custom PCR arrays contained primers for genes coding for DNA repair
enzymes and housekeeping genes (ACTB & GAPDH) and positive and negative PCR
controls (Table 2.4). The absolute concentrations of intact DNA in the template were
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calculated using the web-based PCR Array Data Analysis Software provided by the
manufacturer (SABiosciences).
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PPC: Positive PCR Control; HGDC: Human Genomic DNA Contamination

H

G

F

E

D

C

B

A

1

PPC
16

8

C

7

FEN1

HGD

H

6

XPA

GAPD

13

5

XRCC1

ACTB

12

4

UNG

EXO1

11

3

POLB

ATM

0

2

OGG1

RAD5

1A

1

APEX1

MRE1

PARP1

2

24

FEN1

23

XPA

22

XRCC1

21

UNG

20

POLB

19

OGG1

18

APEX1

17

PARP1

3

32

PPC

C

HGD

H

GAPD

29

ACTB

28

EXO1

27

ATM

0

RAD5

1A

MRE1

4

8

FEN1

7

XPA

1

XRCC

5

UNG

4

POLB

3

OGG1

1

APEX

1

PARP

5

16

PPC

15

HGDC

H

GAPD

13

ACTB

12

EXO1

11

ATM

10

RAD50

A

MRE11

6

24

FEN1

23

XPA

1

XRCC

21

UNG

20

POLB

19

OGG1

1

APEX

1

PARP

7

32

PPC

C

HGD

H

GAPD

29

ACTB

28

EXO1

27

ATM

0

RAD5

1A

MRE1

8

8

FEN1

7

XPA

6

XRCC1

5

UNG

4

POLB

3

OGG1

2

APEX1

1

PARP1

9

16

PPC

15

HGDC

14

GAPDH

13

ACTB

12

EXO1

11

ATM

10

RAD50

A

MRE11

10

24

FEN1

23

XPA

22

XRCC1

21

UNG

20

POLB

19

OGG1

18

APEX1

17

PARP1

11

32

PPC

31

HGDC

H

GAPD

29

ACTB

28

EXO1

27

ATM

26

RAD50

A

MRE11

12

Table 2.4. Custom PCR array layout

2.2.10. Protein Isolation and Quantification
Tissue samples were homogenized on ice with a Dounce homogenizer in a buffer
containing 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES),
137 mM NaCl, 4.6 mM KCl, 0.6 mM MgSO4, 0.7 µg/ml pepstatin A, 0.5 µg/ml
leupeptin, 0.5 µg/ml aprotinin and 40 µg/ml PMSF). The resulting homogenate was
centrifuged at 100,000 x g for 1 hour at 4 ◦C. Protein concentration of the supernatant was
measured using the Pierce BCA protein assay (Sigma, St. Louis, MO).
2.2.11. Western Blot Analysis
20 µg of protein of each sample was separated on Criterion 4-15% Tris-HCL
electrophoresis gradient gels followed by transfer to nitrocellulose transfer membranes.
The membranes were then incubated in blocking buffer (5 % milk in 0.5% Tween20/Tris-buffered saline (TTBS)) for 1 hour.

Specific rabbit polyclonal anti-human

primary antibodies against OGG1 (Novus Biologicals, Littleton, CO, USA), UNG, APE1,
POLB, PARP1, XRCC1 & FEN1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
(1:1000 dilution) were added and the membranes were placed on an orbital shaker
overnight at 4°C. Subsequently, the membranes were washed with TTBS three times
followed by incubation with 1:1000 dilution of horseradish peroxidase-labeled goat antirabbit secondary antibody (Jackson Immunoreasearch Laboratories Inc., West Grove, PA,
USA) for 2 hours. The membranes were again washed with TTBS three times and the
bands developed using enhanced chemiluminescence according to the manufacturer’s
instructions (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Band intenisties
were quantified using Scion Image Analysis (NIH). Results are expressed as mean ±
SEM % control immunostaining.
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2.2.12. Enzyme Activity Assays
2.2.12.1. Oligonucleotides
Oligonucleotides used in this study containing 8-oxodG, deoxy-uracil or
tetrahydrofuran (THF) (Midland Certified Reagent Company, Midland, TX) and their
complementary strand sequences are listed in Table 2.5. The lesion-containing
oligonucleotides were 5′-32P-labeled by incubation with [γ-32P] ATP (PerkinElmer,
Boston, MA, USA) and T4 polynucleotide kinase. G25 desalting columns (GE
Healthcare Corp., Piscataway, NJ, USA) were used to remove the unincorporated free [γ32

P] ATP from the reaction mixtures. The 32P-labeled oligonucleotides were annealed to

their complementary strands in annealing buffer (100 mM KCL, 10 mM Tris-HCl, pH 7.8
and 1mM EDTA) by heating the samples at 90°C for 5 min. A double-stranded DNA
substrate containing a double flap region used for the FEN1 activity assay was prepared
by annealing three oligodeoxynucleotides (Table 2.5) (Biosearch Technologies Inc.
Novato, CA, USA) in a reaction buffer containing 50 mM Tris (pH 8), 100 mM KCl and
5mM MgCl2 by heating to 95

C for 5 minutes and subsequent cooling to room

temperature.
2.2.12.2. OGG1 Activity Assay
OGG1 activity assays were carried out as previously described (Croteau and Bohr,
1997; Shao et al., 2008). Briefly, 20 µg of protein were incubated at 37°C for 1 h in a 20
μl reaction mixture containing 40 mM Hepes-KOH (pH 7.6), 5 mM EDTA, 2 mM DTT,
75 mM KCl, 10% glycerol and 88.7 fmol 32P-labeled duplex oligonucleotide (Table 2.5).
Reactions were subsequently quenched by addition of 20 μl of loading buffer containing
90% formamide, 0.002% bromophenol blue, and 0.002% xylene green and heated at
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95°C for 5 min. After cooling to room temperature, the reaction mixture was separated on
a 20% denaturing polyacrylamide gel containing 7 M urea prerun at 18 W for 30 min.
Samples were separated by electrophoresis for 90 min at 16 W using 1X Tris borate
EDTA (TBE) (pH 8.0) as a running buffer. A reaction mixture consisting of 20 μg
protein, heat-inactivated by boiling at 95°C for 5 min before initiating the activity assay
was used as blank for the assay.
Samples were analyzed with NC, MCI, PCAD and LAD samples on the same gel to
allow comparison. Radiolabeled bands were visualized as previously described (Croteau
and Bohr, 1997; Souza-Pinto et al., 1999) and band intensities of the cleaved product and
parent oligonucleotide bands were quantified using Scion Image Analysis (NIH).
Activities were calculated as the amount of radioactivity in the incised product band
relative to the total radioactivity in the lane (incised product + intact duplex
oligonucleotide). Results are expressed as mean ± SEM % control protein activity.
2.2.12.3. UNG Activity Assay
UNG activity assays were as previously described (Maynard et al., 2010; Weissman
et al., 2007). Briefly, 20 μl reaction mixtures containing 70 mM HEPES–KOH (pH 7.4),
5 mM EDTA, 1 mM DTT, 75 mM NaCl, 10% glycerol, 50 fmol

32

P-labeled duplex

oligonucleotide (Table 2.5) and 10 μg of protein were incubated for 1 h at 37°C.
Reactions were subsequently quenched by addition of formamide dye and converted to a
single-strand break product by addition of 50 mM NaOH and incubation at 75°C for 15
minutes. Samples were resolved and analyzed as described for the measurement of
OGG1 activity.
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2.2.12.4. APE1 Activity Assay
APE1 activity assays were carried out as previously described (Maynard et al., 2010;
Weissman et al., 2007). Briefly, 5 µg of protein was incubated at 37°C for 1 h in a 10 μl
reaction mixture containing 20 µg of protein was incubated at 37°C for 1 h in a 20 μl
reaction mixture containing 25 mM HEPES–KOH (pH 7.4), 25 mM KCl, 0.1 mg/ml
BSA, 5 mM MgCl2, 10% glycerol, 0.05% Triton X-100 and 1.0 pmol 32P-labeled duplex
oligonucleotide (Table 2.5). Reactions were terminated and samples resolved and
evaluated as described for the measurement of OGG1 activity.
2.2.12.5. POLB Activity Assay
POLB activity assays were as previously described (Maynard et al., 2010; Weissman
et al., 2007). Samples were diluted in 10mM Tris-HCl (pH 7.4) containing 100 mM KCl.
20 μl reaction mixtures containing 50 mM Tris-HCl (pH 7.4), 50 mM KCl, 1 mM DTT,
75 mM MgCl2, 5% glycerol, 5 µM dCTP (Roche Applied Sciences, Indianapolis, IN,
USA), 4 µCi α32P-dCTP (GE Healthcare Corp., Piscataway, NJ, USA), 1 pmol duplex
gap oligonucleotide (Table 2.5) and 5 μg of protein were incubated for 1 h at 37°C.
Reactions were terminated and samples resolved and evaluated as described for the
measurement of OGG1 activity.
2.2.12.6. FEN1 Activity Assay
FEN1 activity assays were as previously described (Dorjsuren et al., 2011). Briefly,
a 40 μl reaction mixture containing 50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM DTT,
0.01% Tween-20, 5 μg of protein and 1 pmol labeled oligonucleotide (Table 2.5) were
pipetted into a 96-well plate and data collected using a FLx800 fluorescence microplate
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reader (Biotek, Winooski, VT, USA) equipped with standard optics (excitation filter 525
nm and emission filter 598 nm).
2.2.12.7. PARP1 Activity Assay
PARP1 activity assays were carried out as previously described (Adamczyk et al.,
2005; Strosznajder et al., 2000a, b). Briefly 100 μg of protein was incubated in 100 μl
reaction mixture containing 200 uM [14C]NAD (2x105 d.p.m), 100 mM Tris-HCl (pH
8.0), 10 mM MgCl2,1 mM DTT and 50 uM p-amidinophenylmethanesulfonyl fluoride
(APMSF) for 5 minutes at 37°C. Reactions were terminated by addition of 800 μl of 25%
ice-cold trichloroacetic acid (TCA). After collection of the precipitate on Whatman GF/B
filters, it was washed five times with ice-cold 5% TCA, dried and

14

C radioactivity was

measured using a Packard 2500 TR scintillation counter (Thermo Fisher Scientific,
Waltham, MA, USA).
2.2.13. Statistical Analysis
The % oxidative damage values from the fpg reaction and RT-PCR studies are
reported as mean ± SD. Data obtained for gene expression fold change, protein levels and
protein activities were tested for normality using the Wilks-Shapiro test. Statistical
comparisons were carried out using the Mann-Whitney U-test for non-parametrically
distributed data with values reported as the median [range]. For normally distributed data,
statistical comparisons were carried out using ANOVA with Dunnett’s test for individual
comparisons and the values reported as mean ± SEM. P < 0.05 was considered
significant.
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Table 2.5. Names and sequences of oligonucleotides used in protein activity assays
Assay

Sequence

8-

5′-GAA CGA CTG T(oxoG)A CTT GAC TGC TAC TGA T-3′

Oxoguanine

3′-CTT GCT GAC A C T GAA CTG ACG ATG ACT A-5′

incison
Uracil

5′-ATA TAC CGC GG(U) CGG CCG ATC AAG CTT ATT-3′

incision

3′-TAT ATG GCG CC G GCC GGC TAG TTC GAA TAA-5′

AP-site

5′-GAA CGA CTG T(abasic)A CTT GAC TGC TAC TGA T-3′

incision

3′-CTT GCT GAC A C T GAA CTG ACG ATG ACT A-5′

POLB gap- 5′-CTGCAGCTGATGCGC(spacerC3)GTACGGATCCCCGGGTACfilling

3′
3′-GAC GTC GAC TAC GCG GCA TGC CTA GGG GCC CAT G-5′

FEN1

Quencher

incision

5′-CACGTTGACTACCGCTCAATCCTGACGAACACATC-BHQ-2
Flap
5′-TAMRAGATGTCAAGCAGTCCTAACTTTGAGGCAGAGTCCGC
Template
5′-GCGGACTCTGCCTCAAGACGGTAGTCAACGTG-3′
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CHAPTER THREE: RESULTS
3.1. Oxidative DNA Damage in Genes of Proteins Modified during AD
Percent oxidative DNA damage was calculated in the SMTG (a vulnerable brain
region) and cerebellum (a non-vulnerable brain region) of fourteen age-matched NC, five
MCI, thirteen PCAD, thirteen LAD and nine DC subjects. The subject demographics are
shown in Table 3.1. No significant differences were observed in PMI for any of the
subjects studied. Although, there were no significant differences in ages of MCI (91.6 ±
2.7 years), PCAD (85.7 ± 1.8 years) and LAD (81.2 ± 1.6 years) subjects compared to
NC subjects (85.9 + 1.4 years), DC subjects which have an earlier disease age of onset
(70.4 + 5.9 years) were significantly younger than NC subjects. Median Braak staging
scores were significantly (P < 0.05) higher for PCAD (IV), MCI (III), LAD subjects (VI)
and DC subjects (II) compared to NC subjects (I).
Two different DNA isolation methods, phenol-chloroform extraction and extraction
using Qiagen DNeasy Tissue Kit, were compared to determine the method with minimal
artifactual oxidation. Data obtained showed DNA isolated using the DNeasy kit
demonstrated 10-20% more artifactual oxidation compared to phenol-chloroform
extraction method. Based on these results, phenol extraction method was used for DNA
isolation in this project.

Initially, samples were subjected to the Fpg reaction and

oxidative damage as evidenced by fpg cleavage was analyzed using traditional PCR and a
range of primers and visualized using agarose gel electrophoresis. The gels showed
smaller molecular mass bands for fpg treated samples compared to the non-treated
samples but did not provide quantitative data. Hence qPCR was used to quantitatively
determine the % oxidative damage in this study. Primers were designed for PCR and
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qPCR to encompass the coding sequence of each gene and are listed in Table 2.2 and 2.3
respectively. The fluorescent dye SYBR Green was used for detection in the qPCR
reactions. The absence/presence of non-specific amplification in a qPCR reaction was
verified using melt curves. Amplicons highlighted in red in Tables 3.2-3.4 showed a
significant increase (P < 0.05) or a trend towards a significant increase (0.05 < P < 0.1) in
oxidative damage in MCI/PCAD/LAD/DC subjects compared to NC subjects. Results of
this study were non-normally distributed (Wilks-Shapiro test) and are reported as Median
[Range] % of NC values. Oxidative damage data for VADC1I in SMTG and VDAC2D in
cerebellum displayed a normal distribution and are reported as mean (± SEM) % of NC.
All comparisons are based on the average of triplicate experiments. As the data are nonnormally distributed, box and whisker plots were used to describe the results. An
example of a typical box and whisker plot is shown in Figure 3.1. The median value is
represented by the line within the box. The boundaries of the box indicate the 25th (lower
boundary, near zero) and 75th percentile (upper boundary) and the whiskers denote the
10th (whisker below the box) and the 90th percentile (bar above the box). The dots (●)
above and below the whiskers represent extreme data points or outliers.
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Figure 3.1. Example of a box and whisker plot
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3.1.1. VDAC1
Eight sets of VDAC1 primers (Table 2.3.1) were used to examine the % oxidative
damage in the coding sequence of VDAC1 and significant differences in oxidative
damage were observed for 5 amplicons. The results for quantification of oxidative
damage for all 8 amplicons are described in the following section. For the VDAC1A
amplicon (bp 438-613), no significant differences in % oxidative damage were observed
in the SMTG of MCI (184.24 [6.78-244.05]), LAD (71.06 [0-320.84] %) or DC (8.87 [0304.49] %) subjects compared to NC subjects (19.14 [0-366.74] %). Median levels of %
oxidative damage were significantly higher in the SMTG of PCAD subjects (288.36 [0355.38] %) compared to NC subjects for VDAC1A (Figure 3.2A). In the cerebellum, %
oxidative damage was not significantly altered in MCI (0 [0-219.58] %), PCAD (0 [0301.71] %), LAD (72.49 [25.44-281.03] %) or DC (0 [0-298.98] %) subjects compared to
NC subjects (102.83 [0-216.08] %) (Figure 3.2B) for VDAC1A. In the SMTG, there was
a significant increase in median levels of % oxidative damage in LAD (231.53 [0-524.96]
%) and DC (228.7 [62.32-371.39] %) subjects and a trend towards significant increase in
PCAD subjects (217.49 [0-351.31] %) compared to NC subjects (0 [0-380.29] %) for the
VDAC1B amplicon (bp 482-689). No significant changes in the median levels of %
oxidative damage were observed in the SMTG of MCI subjects (214.86 [60.49-357.45]
%) compared to NC subjects for VDAC1B (Figure 3.3A). In the cerebellum, median
levels of % oxidative damage were significantly elevated in DC subjects (0 [0-298.98] %)
compared to NC subjects (111.87 [0-223.75] %) for VDAC1B. In contrast, there were no
significant differences in MCI (0 [0-219.58] %), PCAD (7.5 [0-286.51] %), LAD (126.63
[0-337.72] %) for VDAC1B (Figure 3.3B).
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Analysis of the VDAC1C amplicon (bp 666-913) showed no significant differences
in % oxidative damage in the SMTG of MCI (326.07 [0-439.58] %) but a significant
increase in PCAD (276.22 [94.08-482.44] %), LAD (311.02 [0-494.12] %) and DC
(263.46 [0-528.53] %) subjects compared to NC subjects (69.2 [0-467.70] %) (Figure
3.4A). We observed no significant changes in median levels of % oxidative damage in
the cerebellum of MCI (107.56 [0-283] %), PCAD (137.55 [0-369.19] %), LAD (70.04
[0-362.01] %) or DC (13.83 [0-261.65 %) subjects compared to NC subjects (26.84 [0327.84] %) (Figure 3.4B). Median levels of % oxidative damage showed no significant
differences in the SMTG of MCI (121.81 [0.01-186.61] %), PCAD (149.04 [0-185.66]
%), LAD (53.43 [2.88-143.89] %) or DC (148.09 [0-187.9] %) subjects compared to NC
subjects (126.55 [0-168.46] %) (Figure 3.5A) for the VDAC1D amplicon (bp 695-896).
Similarly, there were no significant differences seen in % oxidative damage for
VDAC1D in the cerebellum of MCI (0 [0-263.16] %), PCAD (0 [0-248.47] %), LAD
(93.88 [0-229.52] %) or DC (48.55 [0-210.79 %) subjects compared NC subjects (104.87
[0-240.47] %) (Figure 3.5B).
Median levels of % oxidative damage were significantly higher in the SMTG of
PCAD (251.5 [0-294.42] %), LAD (192.57 [0-277.07] %) and DC (212.27 [0-301.77] %)
subjects compared to NC subjects (148.07 [0-160.26] %) for the VDAC1E amplicon (bp
722-913). There was a trend towards a significant increase in oxidative damage in SMTG
of MCI (175.67 [123.8-269.36] %) compared to NC subjects (Figure 3.6A). No
significant differences in % oxidative damage were observed for the VDAC1E amplicon
in the cerebellum of MCI (223.13 [0-322.19] %), PCAD (78.16 [0-278.49] %), LAD
(113.23 [0-309.12] %) or DC (143.9 [0-297.43] %) subjects compared to NC subjects
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(69.59 [0-306.2] %) (Figure 3.6B). In the SMTG, there was a significant increase in
median levels of % oxidative damage in LAD (157.87 [0-165.69] %) but no significant
changes in MCI (121.37 [0-140] %), PCAD (139.66 [39.67-162.11] %) or DC (141.42
[18.73-167.65] %) subjects compared to NC subjects (121.92 [0-160.26] %) for the
VDAC1G amplicon (bp 914-1173) (Figure 3.7A). There were no significant differences
observed in % oxidative damage for VDAC1G in the cerebellum of MCI (167.37 [0295.77] %), PCAD (54.69 [0-230.39] %), LAD (101.2 [0-284.02] %) or DC (159.48 [0266.9] %) subjects compared to NC subjects (25.78 [0-285.38] %) (Figure 3.7B).
Analysis of the VDAC1H amplicon (bp 1174-1411) showed no significant
differences in % oxidative damage in the SMTG of MCI (85.34 [0-110.68] %), PCAD
(87.82 [0-146.28] %), LAD (126.09 [0-153.39] %) or DC (122.2 [0-149.48] %) subjects
compared to NC subjects (105.75 [10.83-141.4] %) (Figure 3.8A). Median levels of %
oxidative damage were not significantly different in the cerebellum of MCI (171.58
[69.69-429.3] %), PCAD (0 [0-292.21] %), LAD (106.23 [0-312.94] %) or DC (195.92
[0-383.87] %) subjects compared to NC subjects (67.66 [0-335.75] %) (Figure 3.8B). In
the SMTG, there were no significant differences in average % oxidative damage in MCI
(80.27 ± 15.75 %), PCAD (78.22 ± 12.88 %), LAD (102.75 ± 14.74 %) and DC (113.17
± 9.11 %) subjects compared to NC subjects (100 ± 8.05 %) for the VDAC1I amplicon
(bp 1398-1594) (Figure 3.9A). No significant changes in median levels of % oxidative
damage were observed for VDAC1I in the cerebellum of MCI (131.28 [0-190.85] %),
PCAD (58.5 [0-337.85] %), LAD (45.85 [0-424.78] %) or DC (174.37 [0-350.29] %)
subjects compared to NC subjects (75.46 [0-308.38] %) (Figure 3.9B).
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Table 3.1. Subject demographics for the oxidative damage study
Age

Braak Score PMI

Sex

(Mean ± SEM)

(Median)

(Mean ± SEM)

NC (N = 14)

85.9 ± 1.4

I

2.8 ± 0.2

4M : 10W

MCI (N = 5)

91.6 ± 2.7

III*

2.6 ± 0.2

2M : 3W

PCAD (N = 13) 85.7 ± 1.8

IV*

2.8 ± 0.2

3M : 10W

LAD (N = 13)

81.2 ± 1.6

VI*

3.6 ± 0.4

6M : 7W

DC (N = 9)

70.4 ± 5.9

II*

3.2 ± 0.3

5M : 4W
* P < 0.05

NC: Normal Control; MCI: Mild Cognitive Impairment; PCAD: Preclinical Alzheimer’s
Disease; LAD: Late-stage Alzheimer’s Disease; SEM: Standard Error of Mean; PMI:
Postmortem Interval; M: Men; W: Women
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102.83
[0216.08]
111.87
[0223.75]
26.84 [0327.84]
104.87
[0240.47]
69.59 [0306.2]

25.78 [0285.38]
67.66 [0335.75]
75.46 [0308.38]

19.14 [0366.74]

0
[0380.29]

69.20 [0467.70]

126.55
[0168.46]

148.07
[0224.85]

121.92
[0160.26]

105.75
[10.83141.4]

100 (±
8.05)

VDAC1A

VDAC1B

VDAC1C

VDAC1D

VDAC1E

VDAC1G

VDAC1H

VDAC1I

CER

NC

SMTG

Amplic
on

80.27 (±
15.75)

85.34 [0110.68]

121.37
[0-140]

**175.67
[123.8269.36]

121.81
[0.01186.61]

326.07
[0439.58]

214.86
[60.49357.45]

184.24
[6.78325.69]

SMTG

131.28
[0190.85]

171.58
[69.69429.3]

167.37
[0295.77]

223.13
[0322.19]

0
[0263.16]

107.56
[0-283]

0
[0219.58]

0
[0244.05]

CER

MCI

78.22 (±
12.88)

87.82 [0146.28]

139.66
[39.67162.11]

*251.5
[0294.42]

149.04
[0185.66]

*276.22
[94.08482.44]

**217.4
94
[0351.31]

*288.36
[0355.38]

SMTG

58.5 [0337.85]

0
[0292.21]

54.68
[0230.39]

78.16
[0278.49]

0
[0248.47]

137.55
[0369.19]

7.5 [0286.51]

0
[0301.71

CER

PCAD

102.75
(± 14.74)

126.09
[0153.39]

*157.87
[0165.59]

*192.57
[0277.07]

53.43
[2.88143.89]

*311.02
[0494.12]

*231.53
[0524.96]

71.062
[0320.84]

SMTG

45.85 [0424.78]

106.23
[0312.94]

101.2 [0284.02]

113.23
[0309.12

93.88 [0229.52]

70.04 [0362.01]

126.63
[0337.72]

72.49
[25.44281.03]

CER

LAD

174.37 [0350.29]

195.92 [0383.87]

159.48 [0266.9]

143.9 [0297.43]

48.55 [0210.79]

13.83 [0261.65]

*0
[0298.98]

4.96
[0249.67]

CER

* P < 0.05
** 0.05 < P < 0.1

113.17 (±
9.11)

122.2 [0149.48]

141.42
[18.73167.65]

*212.27
[0-301.77]

148.09 [0187.9]

*263.46
[0-528.53]

*228.7
[62.32371.39]

8.87
[0304.49]

SMTG

DC

Table 3.2. Percent oxidative DNA damage for VDAC1 amplicons (Significant

differences are shown in bold)
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Figure 3.2. Oxidative damage in amplicons for VDAC1A in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.3. Oxidative damage in amplicons for VDAC1B in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.4. Oxidative damage in amplicons for VDAC1C in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.5. Oxidative damage in amplicons for VDAC1D in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.6. Oxidative damage in amplicons for VDAC1E in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.7. Oxidative damage in amplicons for VDAC1G in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.8. Oxidative damage in amplicons for VDAC1H in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.9. Oxidative damage in amplicons for VDAC1I in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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3.1.2. VDAC2
Seven sets of VDAC2 primers (Table 2.3.2) were used to examine levels of
oxidative damage in the coding sequence of VDAC2. The results of oxidative damage
calculated for all the amplicons are discussed in detail in this section. All the amplicons
had a GC content ratio of 44-50% except for the VDAC2A amplicon (bp 24-213) which
had a > 50% GC content ratio. Melt curve analysis of qPCR reactions with primers for
the VDAC2A amplicon showed multiple curves indicating high levels of non-specific
binding. Therefore, the data obtained for VDAC2A could not be used to determine %
oxidative damage. For the VDAC2B amplicon (bp 167-354), no significant differences
in % oxidative damage were observed in the SMTG of MCI (43.71 [0-195.88] %), PCAD
(10.75 [0-457.89] %), LAD (0 [0-202.83] %) or DC (59.88 [0-378.58] %) subjects
compared to NC subjects (21.45 [0-421.84] %) (Figure 3.10A). Similarly, median levels
of % oxidative damage were not significantly different in the cerebellum of MCI (0 [0144.87] %), PCAD (14.42 [0-219.49 %), LAD (229.59 [0-378.58] %) or DC (0 [0224.49] %) subjects compared to NC subjects (31.77 [0-368.24] %) for VDAC2B (Figure
3.10B). For VDAC2C (bp 331-538), % oxidative damage was not significantly altered in
the SMTG of MCI (44.98 [1-251.56] %), PCAD (0 [0-250.21] %), LAD (0 [0-338.84] %)
or DC (0 [0-216.49] %) subjects compared to NC subjects (62.79 [0-414.16] %) (Figure
3.11A). In the cerebellum, analysis of VDAC2C showed no significant differences in
median levels of % oxidative damage in MCI (0 [0-404.84] %), PCAD (0 [0-370.89] %),
LAD (292.5 [0-625.31] %) or DC (3.04 [0-517.63] %) subjects compared to NC subjects
(1.03 [0-484.2] %) (Figure 3.11B).
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No significant differences in median levels of % oxidative damage were observed in
the SMTG of MCI (0 [0-872.98] %), PCAD (0 [0-1053.69] %), LAD (0 [0-667.96] %) or
DC (82.35 [0-1249.86] %) subjects compared to NC subjects (0 [0-778.04] %) (Figure
3.12A) for the VDAC2D amplicon (bp 522-738). In the cerebellum, mean levels of %
oxidative damage were not significantly altered in MCI (127.09 (±39.75) %), PCAD
(114.82 (±22.44) %), LAD (84.44 (±19.12) %) or DC (88.73 (±25.56) %) subjects
compared to NC subjects (100 (±21.2) %) for VDAC2D (Figure 3.12B). Analysis of the
VDAC2E amplicon (bp 726-956), showed no significant differences in % oxidative
damage in the SMTG of MCI (0 [0-573.73] %), PCAD (0 [0-1120.85] %), LAD (0 [0676.49] %) or DC (0 [0-830.88 %) subjects compared to NC subjects (0 [0-1176.67 %)
(Figure 3.13A). In cerebellum, oxidative damage in VDAC2E was not significant
different in MCI (39.67 [0-146.82] %), PCAD (97.59 [0-200.54] %), LAD (94.65 [0190.47] %) or DC (126.19 [0-181.23] %) subjects compared to NC subjects (116.4 [0182.12] %) (Figure 3.13B).
Median levels of % oxidative damage were not significantly different in the SMTG
of MCI (0 [0-93.25] %), PCAD (182.34 [0-383.78] %) or LAD (19.98 [0-257.61] %)
subjects compared to NC subjects (42.47 [0-313.84] %) (Figure 3.14A) for VDAC2G (bp
948-1152). No significant differences in % oxidative damage were observed for
VDAC2G in the cerebellum of MCI (0 [0-276.84] %), PCAD (1.61 [0-198.04] %), LAD
(174.93 [0-351.57] %) or DC (140.05 [0-236.69] %) subjects compared to NC subjects
(5.48 [0-312.73] %) (Figure 3.14B). Quantification of oxidative damage in VDAC2H
amplicon (bp 1126-1310), showed no significant differences in the SMTG of MCI (0 [05291.24] %), PCAD (0 [0-4418.17] %), LAD (0 [0-3746.8] %) or DC (0 [0-4425.36] %)
93

subjects compared to NC subjects (0 [0-1140.54] %) (Figure 3.15A). In the cerebellum,
median levels of % oxidative damage were not significantly different in MCI (116.75
[119.11-275.63] %), PCAD (167.86 [0-265.88] %), LAD (46.86 [0-267.57] %) or DC
(131.67 [0-248.92] %) subjects compared to NC subjects (85.44 [0-278.89] %) for
VDAC2H (Figure 3.15B).
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Table 3.3. Percent oxidative DNA damage for VDAC2 amplicons (There were no
significant differences observed for any of the subjects studied)

VDAC2D

NC
SMTG
21.45
[0421.84
62.79
[0414.16]
0
[0778.04]

VDAC2E

0
[01176.67]

Amplicon
VDAC2B

VDAC2C

VDAC2G

VDAC2H

42.47
[0313.84]
0
[01140.54]

CER
31.77
[0368.24]
1.03
[0484.2]
100 (±
21.2)
116.4
[0182.12]
5.48
[0312.73]
85.44
[0278.89]

MCI
SMTG
43.71
[0195.88]
44.98
[1251.56]
0
[0872.98]
0
[0573.73]
0
[093.25]
0
[05291.24]

CER
0 [0144.87]
0 [0404.84]
127.09
(±
39.75)
39.67
[0146.82]
0 [0276.84]
116.75
[19.11275.63]

PCAD
SMTG
10.75
[0457.89]
0[0250.21]
0
[01053.69]
0
[01120.85]
182.34
[0383.78]
0
[04418.17]

CER
14.42
[0219.49]
0 [0370.89]
114.82
(±
22.44)
97.59
[0200.54]
1.61
[0198.04]
167.86
[0265.88]

LAD
SMTG
0 [0202.83]
0 [0338.84]
0 [0667.96]
0 [0676.49]
19.98
[0257.61]
0 [03746.8]

CER
229.59
[0407.21]
292.5
[0625.31]
84.44
(±
19.12)
94.65
[0190.47]
174.93
[0351.57]
46.86
[0267.57]

DC
SMTG
59.88
[0378.58]
0
[0216.49]
82.35
[01249.86]
0
[0830.88]

0
[04425.36]

* P < 0.05
** 0.05 < P < 0.1
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CER
0 [0224.49]
3.04
[0517.63]
88.73
(±
25.56)
126.19
[0181.23]
140.05
[0236.69]
131.67
[0248.92]
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Figure 3.10. Oxidative damage in amplicons for VDAC2B in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.11. Oxidative damage in amplicons for VDAC2C in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.12. Oxidative damage in amplicons for VDAC2D in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.13. Oxidative damage in amplicons for VDAC2E in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.14. Oxidative damage in amplicons for VDAC2G in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.15. Oxidative damage in amplicons for VDAC2H in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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3.1.3. VDAC3
For quantification of oxidative damage to VDAC3, 5 primer sets encompassing the
coding sequence were used in the study (Table 2.3.3). The results for oxidative damage
observed for all the amplicons are described in detail in this section. In case of the
VDAC3A amplicon (bp 248-447) melt curve analysis of qPCR reactions showed multiple
curves and hence the data obtained for VDAC3A could not be used to determine %
oxidative damage. For the VDAC3B amplicon (bp 367-651), no significant differences in
% oxidative damage were observed in the SMTG of MCI (0 [0-258.07] %), PCAD (36.49
[0-301.24] %), LAD (9.7 [0-238.82] %) or DC (0 [0-291.6] %) subjects compared to NC
subjects (59.85 [0-286.62] %) (Figure 3.16A). Similarly, median levels of % oxidative
damage were not significantly altered in the cerebellum of MCI (0 [0-181.16] %), PCAD
(71.48 [0-152.14] %), LAD (91.72 [0-209.81] %) or DC (49.33 [0-197.9] %) subjects
compared to NC subjects (113.97 [0-201.24] %) in case of VDAC3B (Figure 3.16B).
In SMTG, there were no significant differences in median levels of % oxidative
damage in MCI (84.24 [0-187.08] %), PCAD (20.59 [0-254.05] %), LAD (86.78 [0213.66] %) or DC (63.34 [0-182.46] %) subjects compared to NC subjects (72.99 [0308.28] %) (Figure 3.17A) for the VDAC3C amplicon (bp 540-735). In the cerebellum,
median levels of % oxidative damage were not significantly changed in MCI (66.32 [0399.31] %), PCAD (30.49 [0-287.94] %), LAD (82.21 [0-378.46] %) or DC (182.86 [0327.51] %) subjects compared to NC subjects (34.43 [0-338.25] %) for VDAC3C (Figure
3.17B). For the VDAC3D amplicon (bp 627-865), % oxidative damage was not
significantly altered in the SMTG of MCI (15.4 [0-130.09] %), PCAD (8.18 [0-183.27]
%), LAD (131.5 [0-253.12] %) or DC (48.35 [0-181.7] %) subjects compared to NC
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subjects (56.27 [0-291.79] %) (Figure 3.18A). No significant changes in median levels of
% oxidative damage were observed in the cerebellum of MCI (91.4 [0-304.81] %),
PCAD (111.01 [0-305.05] %), LAD (89.29 [0-238.13] %) or DC (19.65 [0-294.59] %)
subjects compared to NC subjects (60.96 [0-298.08] %) for VDAC3D (Figure 3.18B). In
contrast, there was a significant increase in median levels of % oxidative damage in LAD
subjects (249.8 [0-413.33] %) compared to NC subjects (49.04 [0-288.34] %) in the
SMTG for the VDAC3E amplicon (bp 718-932). There were no significant differences
in % oxidative damage in the SMTG of MCI (121.48 [0-336.77] %), PCAD (228.88 [0447.4] %) or DC (220.95 [0-414.53] %) subjects compared to NC subjects for VDAC3E
(Figure 3.19A). Median levels of % oxidative damage were not significantly changed in
the cerebellum of MCI (70.27 [0-353.98] %), PCAD (29.4 [0-321.21] %), LAD (5.15 [0256.01] %) or DC (145.49 [31.65-288.02] %) subjects compared to NC subjects (83.92
[0-290.73] %) for VDAC3E (Figure 3.19B).
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Table 3.4. Percent oxidative DNA damage for VDAC3 amplicons (Significant

differences are shown in bold)
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Figure 3.16. Oxidative damage in amplicons for VDAC3B in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.17. Oxidative damage in amplicons for VDAC3C in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.18. Oxidative damage in amplicons for VDAC3D in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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Figure 3.19. Oxidative damage in amplicons for VDAC3E in A) SMTG B) Cerebellum
(* P < 0.05; ** 0.05 < P < 0.1)
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3.1.4. IGF2
A progressively increasing percentage of 8-oxoguanine was incorporated into IGF2
gene sequence via PCR. DNA obtained was first transcribed to RNA in vitro and the
RNA was translated to protein in vitro using cell free systems. No product was obtained
for the sample incorporated with 100% 8-oxoguanine. Protein samples from the cell free
expression system were subjected to Western blot analysis and probed for IGF2 using a
specific antibody and

IGF2 enzyme activities were calculated to determine if the

presence of oxidized guanines in DNA can lead to changes in protein levels or protein
activity. The IGF2 enzyme activity was measured as the binding of radiolabeled IGF2
with IGF2 receptors present in human plasma. Samples with 0% 8-oxoguanine (100%
guanine) were used as positive control (PC) for the reaction. Mean ± SEM IGF2 protein
levels (% PC) and protein activity levels (% PC) are shown in Table 3.5. IGF2 protein
levels were significantly increased for 10% (161.47 ± 7.59), 25% (149.32 ± 10.63), 35%
(149.46 ± 9.25) and 50% (146.27 ± 10.19) 8-oxoguanine incorporated samples compared
to PC samples (100 ± 12.07). There was a trend towards significance for IGF2 protein
levels in samples with 75% 8-xoguanine (139.27 ± 16.32) compared to PC samples. For
protein activity levels, significant decreases were seen in samples with 10% (23.89 ±
2.48), 35% (15.36 ± 4.54), 50% (56.95 ± 10.02) and 75% (35.6 ± 9.76) incorporation of
8-oxoguanine compared to PC samples (100 ± 4.65). No significant differences were
observed for samples with 25% 8-oxoguanine incorporated samples (40.78 ± 26.27)
compared to PC samples.
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Table 3.5. Protein levels and Enzyme activity levels of 8-oxoguanine incorporated IGF2
[% PC] (Significant differences are shown in bold)

#
1
2
3
4
5
6

% Oxo
guanine
0 (PC)
10
25
35
50
75

IGF2 protein levels
Mean ± SEM (% PC)
100 ± 12.07
161.47 ± 7.59*
149.32 ± 10.63*
149.46 ± 9.25*
146.27 ± 10.19*
139.27 ± 16.32**

IGF2 activity
Mean ± SEM (% PC)
100 ± 4.65
23.89 ± 2.48*
40.78 ± 26.27
15.36 ± 4.54*
56.95 ± 10.02*
35.6 ± 9.76*
PC = Positive Control
* P < 0.05
** 0.05 < P < 0.1
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3.2. Changes in DNA Repair Enzymes of BER Pathway in AD Subjects
Changes in DNA repair enzymes involved in multiple pathways including OGG1,
UNG, APE1, POLB, FEN1, PARP1, XRCC1, EXO1, RAD50, XPA, MRE11A and ATM
were determined in the SMTG (a vulnerable brain region) and cerebellum (a nonvulnerable brain region) of fifteen age-matched NC, six MCI, thirteen PCAD, fourteen
LAD and twelve DC subjects. Subject demographic data are shown in Table 2.1. There
were no significant differences in PMI between MCI/PCAD/LAD/DC subjects compared
to age-matched NC subjects. No significant differences were observed in age of MCI
(91.0 ± 2.2 years), PCAD (85.7 ± 1.8 years) or LAD (81.4 ± 1.4 years) subjects compared
to age-matched NC subjects (86.3 ± 1.4 years) athough DC (68.9 ± 4.8 years) subjects
were significantly younger than NC subjects. Braak staging scores are reported as median
values and were significantly higher (P < 0.05) for MCI (III), PCAD (IV) LAD (VI) and
DC subjects (II) compared to age-matched NC subjects (I). The data for this study were
tested for normality using the Wilks-Shapiro test. Non-normally distributed is reported as
Median [Range] and normally distributed data is described as mean (± SEM). The results
for this study are summarized in Table 3.9.
3.2.1. Gene Expression
Gene expression of 12 genes involved in multiple DNA repair pathways including
OGG1, UNG, APE1, POLB, FEN1, PARP1, XRCC1, EXO1, RAD50, XPA, MRE11A
and ATM was analyzed using the DNA repair pathway RT2 custom PCR array
(SABiosciences) (Table 2.4) and quantitative reverse transcription PCR in the SMTG and
the cerebellum from PCAD, MCI, LAD, DC and age-matched NC subjects. The
housekeeping genes, β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
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were used for normalization. Results are expressed in terms of fold change in gene
expression in MCI/PCAD/LAD/DC subjects compared to age-matched NC subjects. Fold
change is defined as the ratio of 2−ΔCt values for samples from varied disease stages
(MCI, PCAD, LAD) to the average 2−ΔCt value of NC samples. Positive and negative
controls were run on each plate to verify genomic integrity and PCR efficiency. The data
were found to be non-normally distributed as determined by the Wilks-Shapiro test for
normality. Table 3.6 shows the fold change values obtained for expression of specific
genes in specimens of SMTG and cerebellum as median [range] for NC, MCI, PCAD,
LAD and DC subjects.
A statistically significant increase (P < 0.05) was observed in fold change for OGG1
in SMTG of PCAD (1.6 [1.34-4.14]) and LAD (2.06 [0.79-3.85]) subjects compared to
NC subjects (1.21 [0.19-1.49]) whereas SMTG samples from MCI (1.33 [0.55-1.55]) and
DC (1.14 [0.13-3.17]) subjects showed no significant changes in OGG1 gene expression
compared to NC subjects. OGG1 gene expression levels in cerebellum showed no
significant differences in MCI (1.11 [0.7-1.56]), PCAD (1.12 [0.75-1.96]), LAD (1.12
[0.67-3.68]) or DC (1.28 [0.55-2.09]) subjects compared to NC subjects (0.98 [0.272.15]). Levels of UNG expression were significantly increased in the SMTG of PCAD
(1.72 [0.56-5.4]), LAD (1.59 [0.29-4.09]) and DC (2.48 [0.59-7.76]) subjects but showed
no change in SMTG of MCI subjects (1.29 [0.85-4.65]) compared to NC subjects (0.89
[0.45-1.79]). UNG gene expression levels in cerebellum were not significantly changed
for any of the subject groups studied including MCI (0.96 [0.41-2.25]), PCAD (1.07
[0.49-2.2]), LAD (0.99 [0.43-4.89]) and DC (1.05 [0.5-2.6]) subjects compared to NC
subjects (0.99 [0.35-1.87]).
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No significant differences in the median levels of fold change in gene expression of
APE1 were observed in the SMTG of MCI (0.91 [0.46-3.4]), PCAD (0.97 [0.4-1.63])),
LAD (1.19 [0.66-2.71]) and DC (0.73 [0.02-1.7]) subjects compared to NC subjects (1.02
[0.14-1.4]). In cerebellum, median fold change in APE1 expression levels were
comparable for all the disease states studied including MCI (1.02 [0.47-1.12]), PCAD
(0.85 [0.48-2.12]), LAD (1.07 [0.76-2.06]) and DC (1.14 [0.76-1.89]) subjects compared
to NC subjects (0.95 [0.66-1.9]). Fold change in POLB expression levels were not
significantly different in SMTG of MCI (1.23 [0.92-2.46]) and DC (1.02 [0.1-2.25])
subjects but showed a statistically significant increase in PCAD (1.35 [1.05-2.22]) and
LAD (1.32 [0.84-3.27]) subjects compared to NC subjects (1.04 [0.38-1.34]).
Comparison of fold change in POLB expression levels across the disease spectrum in the
cerebellum showed no significant changes in MCI (1.3 [0.64-3.3]), PCAD (1.28 [0.243.51]) and LAD (1.2 [0.4-4.81]) compared to NC subjects (1.15 [0.1-1.3]). In contrast,
there was a significant increase in fold change of POLB expression in the cerebellum of
DC (1.73 [0.47-3.14]) subjects compared to NC subjects.
In the SMTG, there were no significant changes in median levels of fold change in
FEN1 expression levels in MCI (0.89 [0.38-1.39]), PCAD (1.05 [0.32-3.53]), LAD (1.1
[0.21-2.51]) or DC (1.24 [0.11-2.18]) subjects compared to NC subjects (0.86 [0.412.44]). Median levels of fold change in FEN1 expression levels were also significantly
unchanged in the cerebellum of MCI (0.98 [0.75-1.45]), PCAD (1.17 [0.69-1.84]), LAD
(1.29 [0.74-3.14]) and DC (1.33 [0.49-2.27]) subjects compared to NC subjects (1.04
[0.49-1.32]). For PARP1 expression, there were no significant differences in the SMTG
of MCI (0.94 [0.68-1.26]), PCAD (0.99 [0.29-2.01]) or DC (0.98 [0.02-2.82]) subjects
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although there was a significant increase in fold change in LAD subjects (1.54 [0.673.05]) compared to NC subjects (0.83 [0.41-2.44]). No significant differences in fold
change in PARP1 expression levels were observed in the cerebellum of MCI (1.0 [0.641.55]), PCAD (1.32 [0.35-5.11]), LAD (1.02 [0.53-4.15]) and DC (1.1 [0.5-2.86])
subjects compared to NC subjects (0.73 [0.47-3.27]).
In SMTG, median fold change in XRCC1 expression levels were comparable
throughout the progression of AD including MCI (1.05 [0.75-2.09]), PCAD (1.12 [0.477.08]) and LAD (1.41 [0.57-4.05]) subjects and also in DC (1.25 [0.61-6.19]) subjects
compared to NC subjects (0.92 [0.35-1.59]). There was no significant difference
observed in fold change in XRCC1 expression in the cerebellum of MCI (0.87 [0.511.31]), PCAD (1.13 [0.53-1.76]), LAD (0.86 [0.7-8.39]) and DC (0.89 [0.51-2.0])
subjects compared to NC subjects (0.8 [0.32-3.15]). No significant changes in the median
levels of fold change in EXO1 expression levels were observed in the SMTG of MCI
(0.44 [0.11-2.19]), PCAD (0.33 [0.11-1.97]), LAD (0.55 [0.22-2.41]) and DC (0.66
[0.22-12.69]) subjects compared to NC subjects (0.44 [0.11-7.0]). In the cerebellum,
median levels of fold change in EXO1 expression levels were not significantly different
in MCI (0.61 [0.4-1.13]), PCAD (0.48 [0.16-4.44]), LAD (0.36 [0.16-13.39]) and DC
(0.48 [0.08-18.55]) subjects compared to NC subjects (0.32 [0.16-7.1]).
Fold change in RAD50 expression levels were not significantly different in SMTG
of MCI (0.9 [0.41-1.69]), PCAD (0.9 [0.23-2.82]) or DC (0.79 [0.11-4.36]) subjects but
showed a statistically significant increase in LAD subjects (1.35 [0.3-3.61]) compared to
NC subjects (0.83 [0.08-3.68]). In contrast, no significant differences in fold change in
RAD50 expression levels were observed in the cerebellum of MCI (1.0 [0.78-1.71]),
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PCAD (0.78 [0.15-2.55]), LAD (1.08 [0.24-4.97]) or DC (0.93 [0.36-5.33]) subjects
compared to NC subjects (0.82 [0.42-2.73]). In SMTG, median fold change in XPA
expression levels were comparable throughout the progression of AD including MCI
(0.99 [0.47-1.71]), PCAD (0.82 [0.6-9.6]) and LAD (1.04 [0.46-2.87]) and also in DC
(1.06 [0.58-3.29]) subjects compared to NC subjects (0.82 [0.35-2.62]). Median levels of
fold change in XPA expression levels were not significantly altered in the cerebellum of
MCI (1.0 [0.15-1.92]), PCAD (1.15 [0.58-3.28]), LAD (1.07 [0.47-6.12]) and DC (0.9
[0.48-1.96]) subjects compared to NC subjects (0.88 [0.35-2.33]).
No significant changes in median levels of fold change in MRE11A were observed
in the SMTG of MCI (1.27 [0.32-2.81]), PCAD (0.77 [0.27-2.81]), LAD (0.93 [0.455.12]) or DC (1.09 [0.13-5.25]) subjects compared to NC subjects (0.91 [0.27-2.94]). In
the cerebellum, median levels of fold change in MRE11A expression levels were not
significantly changed in MCI (1.36 [0.82-2.23]), PCAD (1.38 [0.5-2.3]), LAD (1.2 [0.113.57]) or DC (1.59 [0.22-6.07]) subjects compared to NC subjects (0.88 [0.3-1.94]). In
case of the fold change in ATM expression levels, there were no significant differences in
the SMTG of MCI (0.71 [0.46-2.13]), PCAD (0.72 [0.16-2.64]), LAD (1.13 [0.44-4.81])
and DC (0.63 [0.09-3.77]) subjects compared to NC subjects (0.79 [0.14-2.61]). There
were no significant differences observed in fold change in ATM expression levels in the
cerebellum of MCI (1.08 [0.83-1.91]), PCAD (1.11 [0.53-5.27]), LAD (1.27 [0.5210.24]) or DC (1.12 [0.44-2.74]) subjects compared to NC subjects (1.0 [0.21-1.93]).
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Table 3.6. Fold change in expression of DNA repair genes as determined by DNA
Damage Repair PCR Custom PCR array (Bold numbers indicate significant difference)
Gene

OGG1

UNG

APE1

POLB

NC

MCI

PCAD

LAD

DC

Median (Range)

Median

Median

Median

Median

(Range)

(Range)

(Range)

(Range)

SMTG

Cer

SMTG

Cer

SMTG

Cer

SMTG

Cer

SMTG

Cer

1.21

0.98

1.33

1.11

*1.6

1.12

*2.06

1.12

1.14

1.28

[0.19-

[0.27-

[.55-

[0.7-

[1.34-

[0.75-

[0.79-

[0.67-

[0.13-

[0.55-

1.49]

2.15]

1.55]

1.56]

4.14]

1.96]

3.85]

3.68]

3.17]

2.09]

0.89

0.99

1.29

0.96

*1.72

1.07

*1.59

0.99

*2.48

1.05

[0.45-

[0.35-

[0.85-

[0.41-

[0.56-

[0.49-

[0.29-

[0.43-

[0.59-

[0.5-

1.79]

1.87]

4.65]

2.25]

5.4]

2.2]

4.09]

4.89]

7.76]

2.6]

1.02

0.95

0.91

1.02

0.97

0.85

1.19

1.07

0.73

1.14

[0.14-

[0.66-

[0.46-

[0.47-

[0.4-

[0.48-

[0.66-

[0.76-

[0.02-

[0.76-

1.4]

1.9]

3.4]

1.12]

1.63]

2.12]

2.71]

2.06]

1.7]

1.89]

1.04

1.15

1.23

1.3

*1.35

1.28

*1.32

1.2

1.02

*1.73

[0.38-

[0.1-1.3]

[0.92-

[0.64-

[1.05-

[0.24-

[0.84-

[0.4-

[0.1-

[0.47-

2.46]

3.3]

2.22]

3.51]

3.27]

4.81]

2.25]

3.14]

1.34]
FEN1

PARP1

XRCC1

0.86

1.04

0.89

0.98

1.05

1.17

1.1

1.29

1.24

1.33

[0.41-

[0.49-

[0.38-

[0.75-

[0.32-

[0.69-

[0.21-

[0.74-

[0.11-

[0.49-

2.44]

1.32]

1.39]

1.45]

3.53]

1.84]

2.51]

3.14]

2.18]

2.27]

0.83

0.73

0.94

1.0

0.99

1.32

*1.54

1.02

0.98

1.1

[0.17-

[0.47-

[0.68-

[0.64-

[0.29-

[0.35-

[0.67-

[0.53-

[0.02-

[0.5-

3.03]

3.27]

1.26]

1.55]

2.01]

5.11]

3.05]

4.15]

2.82]

2.86]

0.92

0.8

1.05

0.87

1.12

1.13

1.41

0.86

1.25

0.89

[0.35-

[0.32-

[0.75-

[0.51-

[0.47-

[0.53-

[0.57-

[0.7-

[0.61-

[0.51-

1.59]

3.15]

2.09]

1.31]

7.08]

1.76]

4.05]

8.39]

6.19]

2.0]
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Table 3.6. Contd. Fold change in expression of DNA repair genes as determined by DNA
Damage Repair PCR Custom PCR array (Bold numbers indicate significant difference)
Gene

NC

MCI

PCAD

LAD

DC

Median

Median

Median

Median

Median

(Range)

(Range)

(Range)

(Range)

(Range)

SMTG

Cer

SMTG

Cer

SMTG

Cer

SMTG

Cer

SMTG

Cer

EXO1

0.44
[0.117.0]

0.32
[0.167.1]

0.44
[0.112.19]

0.61
[0.41.13]

0.33
[0.111.97]

0.48
[0.164.44]

0.55
[0.222.41]

0.36
[0.1613.39]

0.66
[0.2212.69]

0.48
[0.0818.55]

RAD50

0.83
[0.083.68]

0.82
[0.422.73]

0.9
[0.411.69]

1.0
[0.781.71]

0.9
[0.232.82]

0.78
[0.152.55]

*1.35
[0.33.61]

1.08
[0.244.97]

0.79
[0.114.36]

0.93
[0.365.33]

XPA

0.82
[0.352.62]

0.88
[0.352.33]

0.99
[0.471.71]

1.0
[0.151.92]

0.82
[0.69.6]

1.15
[0.583.28]

1.04
[0.462.87]

1.07
[0.476.12]

1.06
[0.583.29]

0.9
[0.481.96]

MRE11A

0.91
[0.272.94]

0.88
[0.31.94]

1.27
[0.322.81]

1.36
[0.822.23]

0.77
[0.272.81]

1.38
[0.52.3]

0.93
[0.455.12]

1.2
[0.113.57]

1.09
[0.135.25]

1.59
[0.226.07]

ATM

0.79
[0.142.61]

1.0
[0.211.93]

0.71
[0.462.13]

1.08
[0.831.91]

0.72
[0.162.64]

1.11
[0.535.27]

1.13
[0.444.81]

1.27
[0.5210.24]

0.63
[0.093.77]

1.12
[0.442.74]

* P < 0.05
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Figure 3.20. Fold change in gene expression for OGG1 in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.21. Fold change in gene expression for UNG in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.22. Fold change in gene expression (SMTG) for APE1 in A) SMTG B)
Cerebellum
(* P < 0.05)
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Figure 3.23. Fold change in gene expression for POLB in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.24. Fold change in gene expression for FEN1 in A) SMTG B) Cerebellum
(* P < 0.05)

122

3.5

Fold change normalized to NC

3.0

*

A

2.5

NC
MCI
PCAD
LAD
DC

2.0
1.5
1.0
0.5
0.0

6

NC
MCI
PCAD
LAD
DC

B
Fold change normalized to NC

5

4

3

2

1

0

Figure 3.25. Fold change in gene expression for PARP1 in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.26. Fold change in gene expression for XRCC1 in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.27. Fold change in gene expression for EXO1 in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.28. Fold change in gene expression for RAD50 in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.29. Fold change in gene expression for XPA in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.30. Fold change in gene expression for MRE11A in A) SMTG B) Cerebellum
(* P < 0.05)
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Figure 3.31. Fold change in gene expression for ATM in A) SMTG B) Cerebellum
(* P < 0.05)
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3.2.2. Protein levels
To determine if changes in gene expression correspond to changes in protein level,
20 µg protein specimens from samples used for the gene expression studies were
subjected to Western blot analysis and separately probed for proteins involved in the BER
pathway including OGG1, UNG, APE1, POLB, FEN1, PARP1 and XRCC1, using
specific antibodies. A representative image of Western blots for the seven proteins in
SMTG is shown in Figure 3.32. Median [Range] or Mean ± SEM OGG1, UNG APE1,
POLB, FEN1, PARP1 and XRCC1 protein levels (% NC) are shown in Table 3.7. OGG1
protein levels were not significantly different in SMTG of MCI (76.16 [33.31-108.11] %
NC) or LAD (92.57 [52.26-164.13] % NC) subjects but showed a statistically significant
increase in PCAD subjects (107.02 [75.96-178.47] % NC) and a significant decrease in
DC subjects (50.98 [4.1-79.45] % NC) compared to NC subjects (99.24 [65.31-194.71] %
NC) (Figure 3.33A). In contrast, no significant differences in OGG1 protein levels were
observed in the cerebellum of MCI (106.18 (±13.33) % NC), PCAD (104.97 (±6.79) %
NC), LAD (90.82 (±6.92) % NC) or DC (104.83 (±9.68) % NC) subjects compared to
NC (100 (±6.61) % NC) subjects (Figure 3.33B). In SMTG, median UNG protein levels
were comparable throughout the progression of AD including MCI (88.98 [67.89-215.66]
% NC), PCAD (99.07 [63.93-148.97] % NC) and LAD (97.47 [57.39-153.74] % NC)
subjects compared to age-matched NC (94.72 [79.76-142.91] % NC) subjects and DC
(87.19 [67.26-174.25] % NC) subjects (Figure 3.34A). UNG levels were significantly
higher in the cerebellum of LAD subjects (124.3 [75.73-241.98] % NC) but showed no
significant differences in MCI (113.27 [41.28-172.23] % NC), PCAD (110.52 [80.09-
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253.3] % NC) or DC (115.52 [75.38-214.37] % NC) subjects compared to NC subjects
(97.37 [82.17-123.99] % NC) (Figure 3.34B).
A statistically significant decrease in APE1 protein was observed in SMTG of MCI
(86.73 [78.63-98.61] % NC) and DC (71.17 [52.98-86.89] % NC) subjects. In contrast,
no significant differences were observed in PCAD (110.02 [85.76-156.87] % NC) or
LAD (96.14 [67.39-117.9] % NC) subjects compared to NC subjects (101.04 [87.4111.47] % NC) (Figure 3.35A). APE1 levels were not significantly different in the
cerebellum for any of the subject groups studied including MCI (124.03 [80.21-160.84]
% NC), PCAD (112.84 [62.81-263.69] % NC), LAD (109.53 [13.07-289.69] % NC) or
DC (105.14 [21.29-139.31] % NC) subjects compared to NC subjects (93.69 [37.47156.38] % NC) (Figure 3.35B). In the SMTG, there was a significant decrease in mean
levels of POLB protein in MCI subjects (76.09 (±5.39) % NC) compared to NC subjects
(100 (±3.42) % NC). No significant changes in mean POLB protein levels were observed
in the SMTG of PCAD (100.28 (±8.11) % NC), LAD (123.4 (±11.79) % NC) or DC
(85.89 (±16.59) % NC) subjects compared to NC subjects (100 (±3.42) % NC) (Figure
3.36A). In the cerebellum, median POLB protein levels were not significantly altered in
MCI (101.33 [52.09-166.54] % NC), PCAD (109.93 [52.9-246.08] % NC), LAD (110.61
[62.34-310.57] % NC) or DC (90.5 [37.25-196.69] % NC) subjects compared to NC
subjects (99.14 [59.7-183.28] % NC) (Figure 3.36B).
Mean FEN1 protein levels were significantly higher in the SMTG of PCAD (146.42
(±9.15) % NC) and LAD (132.21 (±10.24) % NC) subjects and showed no change in
SMTG of MCI subjects (90.93 (±6.0) % NC) compared to NC subjects (98.59 (±4.3) %
NC). In contrast, a significant decrease in FEN1 protein levels was observed in the
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SMTG of DC subjects (63.98 (±5.63) % NC) compared to NC subjects (Figure 3.37A).
Median FEN1 protein levels were not significantly altered in the cerebellum of MCI (98
[39.09-161.83] % NC), PCAD (120.23 [54.86-141.24] % NC) or LAD (154.97 [23.18195.74] % NC) subjects but were significantly elevated in DC subjects (132.6 [116.37329.44] % NC) compared to NC subjects (99.14 [59.7-183.28] % NC) (Figure 3.37B).
Median PARP1 protein levels were significantly decreased in SMTG of PCAD (33.1
[17.53-121.42] % NC) and LAD (42.33 [13.66-193.82] % NC) subjects but was not
altered in MCI (45.39 [22.59-135.98] % NC) or DC (61.14 [14.26-253.39] % NC)
subjects compared to NC subjects (102.92 [23.32-238.01] % NC) (Figure 3.38A). In the
cerebellum, mean PARP1 protein levels were significantly decreased in LAD (48.43
(±6.35) % NC) and DC (43.85 (±7.73) % NC) subjects but showed no change in MCI
(78.75 (±6.57) % NC) or PCAD (108.41 (±9.22) % NC) subjects compared to NC
subjects (98.2 (±9.74) % NC) (Figure 3.38B). A statistically significant increase in
XRCC1 protein levels was observed in SMTG of MCI (126.8 [117.33-146.41] % NC)
and PCAD (126.64 [96.93-138.54] % NC) subjects but no significant changes were
observed in SMTG of LAD (109.54 [77.87-135.92] % NC) or DC (99.6 [87.87-132.5] %
NC) subjects compared to age-matched NC subjects (99.89 [85.7-113.16] % NC) (Figure
3.39A). Median levels of XRCC1 protein throughout the progression of AD including
MCI (101.54 (±7.29) % NC), PCAD (99.76 (±8.77) % NC) and LAD (102.22 (±11.41) %
NC) subjects were comparable to those in age-matched NC subjects (100 (±3.42) % NC)
in the cerebellum. However, XRCC1 protein levels in the cerebellum of DC subjects
(144.73 (±24.55) % NC) were significantly increased compared to NC subjects (Figure
3.39B).
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Table 3.7: Protein levels of DNA repair genes [% NC] (Bold numbers indicate significant

difference)
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Figure 3.32A. Representative images of Western blots for OGG1, UNG, APE1 and POLB
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Figure 3.32B. Representative images of Western blots for FEN1, PARP1 and XRCC1
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Figure 3.33. Protein Levels of OGG1 (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
136

240
220

NC
MCI
PCAD
LAD
DC

A

UNG Protein Levels (% NC)

200
180
160
140
120
100
80
60
40

300

NC
MCI
PCAD
LAD
DC

B
UNG Protein Levels (% NC)

250

200

150

100

50

0

Figure 3.34. Protein Levels of UNG (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
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Figure 3.35. Protein Levels of APE1 (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
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Figure 3.36. Protein Levels of POLB (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
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Figure 3.37. Protein Levels of FEN11 (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
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Figure 3.38. Protein Levels of PARP1 (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)

141

150
140

XRCC1 Protein Levels (% NC)

*

A

NC
MCI
PCAD
LAD
DC

*

130
120
110
100
90
80
70

400

XRCC1 Protein Levels (% NC)

350

B

*

300

NC
MCI
PCAD
LAD
DC

250
200
150
100
50
0

Figure 3.39. Protein Levels of XRCC1 (% NC) in A) SMTG and B) Cerebellum
(* P < 0.05)
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3.2.3

Enzyme activity levels

Enzyme activities for OGG1, UNG, APE1, POLB, FEN1 and PARP1 were
calculated to determine if changes in protein levels led to a corresponding
enhancement/loss in protein activity. OGG1, UNG and APE1 activity was measured by
examining their ability to cleave radiolabeled duplex DNA oligos (Table 2.5) containing
a single 8-oxodG, deoxy-uracil or tetrahydrofuran lesion by electrophoresis on a 20%
denaturing gel. The band intensities of the intact oligonucleotide and the incision product
of each sample were quantified and incision activities of each assay were calculated as
the percentage of the amount of radioactivity in the incised product band relative to the
total radioactivity in the lane (incised product + intact duplex oligonucleotide). Activity
of POLB was measured as the incorporation of a radiolabeled single nucleotide (α32PdCTP) into a 34-mer oligonucleotide containing a single gap followed by electrophoresis
on a 20% denaturing gel. A dsDNA substrate containing flap strands prepared from three
oligonucleotides (Table 2.5) labeled with a 6-TAMRA (fluorophore donor) at the 5’ end
and BHQ-2 (fluorophore quencher) at the 3’ end was used in the FEN1 activity assay.
Enzymatic cleavage of the flap strand by FEN1 leads to the release of a 6-TAMRA
labeled short single stranded product and consequently an increase in fluorescence.
[adenine-14C]NAD was used as the substrate to determine PARP1 activity by
measurement of radioactive

14

C incorporation into a TCA-insoluble material (protein-

bound [14C](ADP-ribose)n). Enzyme activity levels for OGG1, UNG, APE1, POLB,
FEN1 and PARP1 are shown in Table 3.8 and are reported as median [range] or mean
(±SEM) % NC activity. Representative images for activity assays of OGG1, UNG,
APE1 and POLB in SMTG are shown in Figure 3.40. No activity was observed in
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representative protein samples heat-inactivated by boiling at 95°C before initiating the
activity assays (blank).
OGG1 incision activity was not significantly different in the SMTG of MCI (123.89
[95.89-144.47] % NC), PCAD (99.65 [91.62-106.35] % NC), LAD (99.81 [87.92-101.73]
% NC) or DC (99.07 [94.81-103.05] % NC) subjects compared to NC subjects (100
[87.15-111.92] % NC) (Figure 3.41A). Comparison of OGG1 activity across the disease
spectrum in the cerebellum showed no significant changes in MCI (93.35 (±2.5) % NC),
PCAD (97.81 (±2.51) % NC), LAD (101.56 (±2.1) % NC) or DC (96.99 (±1.7) % NC)
subjects compared to NC subjects (99.19 (±1.48) % NC) (Figure 3.41B). UNG activity
levels on the other hand were significantly higher in the SMTG of MCI (133.72 (±4.64)
% NC), PCAD (149.67 (±4.42) % NC) and LAD (134.61 (±8.7) % NC) subjects
compared to NC subjects (100 (±4.82) % NC). Mean levels of UNG activity were not
significantly changed in SMTG of DC subjects (122.71 (±11.19) % NC) compared to NC
subjects (Figure 3.42A). No significant differences were observed in UNG activity in
CER of any of the diseased subjects studied including MCI (110.91 (±10.05) % NC),
PCAD (120.94 (±7.44) % NC), LAD (106.81 (±6.5) % NC) and DC (91.58 (±11.7) %
NC) subjects compared to NC subjects (100 (±6.05) % NC) (Figure 3.42B).
Levels of APE1 activity were not significantly changed in samples from SMTG of
MCI (107.3 (±6.53) % NC), LAD (111.29 (±5.65) % NC) and DC (109.48 (±6.46) %
NC) subjects but were significantly elevated in samples from PCAD subjects (116.42
(±5.99) % NC) compared to those from NC subjects (100 (±3.64) % NC) (Figure 3.43A).
In contrast, APE1 activity levels were significantly reduced in the cerebellum of PCAD
(77.38 [12.12-98.74] % NC) and LAD (61.09 [20.75-125.45] % NC) subjects compared
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to age-matched NC subjects (99.95 [61.3-145.03] % NC). Median APE1 activity levels
showed no significant changes in cerebellum of MCI subjects (128.4 [88.87-139.37] %
NC) or DC (47.01 [16.38-144.87] % NC) subjects compared to NC subjects (Figure
3.43B). A statistically significant increase in POLB enzyme activity was observed in
SMTG of MCI (113.25 [106.21-124.93] % NC) and PCAD (114.55 [86.81-146.31] %
NC) subjects compared to NC subjects (101.82 [79.54-121.2] % NC). No significant
changes in POLB enzyme activity levels were observed in SMTG of LAD (105.73
[94.47-140.29] % NC) or DC (100.66 [91.22-116.09] % NC) subjects compared to NC
subjects (Figure 3.44A). Mean POLB enzyme activity levels were not significantly
altered in the cerebellum of MCI (106.85 (±3.98) % NC), LAD (105.03 (±3.2) % NC) or
DC subjects (106.55 (±4.59) % NC) but were significantly elevated in PCAD (115.56
(±3.48) % NC) subjects compared to NC subjects (98.69 (±2.66) % NC) (Figure 3.44B).
Mean levels of FEN1 activity were significantly decreased in SMTG of PCAD (88.5
(±2.47) % NC), LAD (81.79 (±4.41) % NC) and DC (57.49 (±7.13) % NC) subjects but
showed no change in MCI subjects (92.77 (±3.31) % NC) compared to NC subjects (100
(±2.7) % NC) (Figure 3.45A). Comparison of FEN1 activity across the disease spectrum
in the cerebellum showed no significant changes in MCI (108.64 (±13.39) % NC), PCAD
(105.92 (±14.06) % NC) or LAD (71.96 (±9.4) % NC) subjects compared to NC subjects
(100 (±7.86) % NC). A statistically significant decrease in FEN1 enzyme activity was
observed in cerebellum of DC subjects (65.26 (±6.1) % NC) compared to NC subjects
(Figure 3.45B). In SMTG, median PARP1 enzyme activity levels were not significantly
different in MCI (65.84 [16.38-235.67] % NC), PCAD (100.82 [4.93-295.05] % NC) or
DC (63.21 [36.74-502.77] % NC) subjects but were significantly elevated in LAD
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subjects (229.08 [92.35-498.61] % NC) compared to NC subjects (56.19 [5.56-379.45] %
NC) (Figure 3.46A). Median PARP1 activity levels were not significantly altered in the
cerebellum of MCI subjects (147.89 [130.41-188.95] % NC) but were significantly
higher in PCAD (213.1 [44.17-252.59] % NC), LAD (170.43 [63.84-338.08] % NC) and
DC (295.34 [82.95-410.47] % NC) subjects compared to NC subjects (72.74 [19.26243.66] % NC) (Figure 3.46B).
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Figure 3.40A. Representative images of activity assays for OGG1 and UNG
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Figure 3.40B. Representative images of activity assays for APE1 and POLB
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Table 3.8: Enzyme activity Levels of DNA repair genes [% NC] (Bold numbers indicate

significant difference)
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Figure 3.41. Protein Activity Levels of OGG1 (% NC) in A) SMTG and B) Cerebellum
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Figure 3.44. Protein Activity Levels of POLB (% NC) in A) SMTG and B) Cerebellum
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Table 3.9. Summary of results for BER pathway
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↑
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Chapter 4: Discussion
Oxidative stress is considered one of the many contributing factors to the
pathogenesis of AD. Reactive oxygen species (ROS), a major contributor to oxidative
stress, are continuously produced in the human body by both endogenous (byproducts of
cellular metabolism) and exogeneous (smoking, pollution, radiation) methods. ROSmediated oxidative damage is extremely critical in non-dividing postmitotic cells like
neurons, as the damaged cells cannot be replaced by new ones. Oxidative damage to the
nucleic acid framework (nDNA, mtDNA and RNA) in such cells can lead to neuronal
dysfunction and loss associated with aging and neurodegenerative processes like AD
(Beal, 2005; Lu et al., 2004; Moreira et al., 2008; Nunomura et al., 1999). Multiple
studies have shown an increase in biomarkers of oxidative DNA damage including 8hydroxyguanine (the predominant marker of oxidative DNA damage), 8-hydroxyadenine,
8-hydroxycytosine, thymine glycol, fapy-adenine, fapy-guanine and 5-hydroxyuracil in
brain tissues, leukocytes and ventricular CSF of AD subjects. Some of these changes
were observed even in the earliest clinically detectable phase of AD (MCI) (Gabbita et
al., 1998; Keller et al., 2005; Lovell and Markesbery, 2001; Lyras et al., 1997;
Markesbery and Carney, 1999; Mecocci et al., 1994; Mecocci et al., 2002; Migliore et al.,
2005; Wang et al., 2005). The reason for increased oxidative damage in the progression
of AD is at present unclear but could possibly be due to an increase in production of ROS
and subsequent increased oxidative stress on DNA or decreased efficiency of DNA repair
mechanisms or a combination of the two.
This dissertation is unique in that both DNA oxidative damage in specific genes
affected during AD and changes in enzymes of the main DNA repair pathway that (BER)
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were studied in a single well-characterized cohort of subjects throughout the progression
of AD. This study utilized DNA, RNA and protein isolated from bulk tissue, so the
results obtained reflect a comprehensive quantity of oxidative damage, gene expression,
protein levels and enzyme activity from both neurons and glia. Previous studies
(Nunomura et al., 1999; Smith et al., 2000a; Smith et al., 2000b) have indicated that
although

AD

brains

often

display

increased

astrocytosis,

8-hydroxyguanine

immunoreactivity was negligible in glial cells but significantly increased in neuronal
cytoplasm. This suggests that DNA oxidative damage and changes in the BER enzymes
measured in this study are largely a neuronal manifestation rather than a glial one.
4. 1. Oxidative DNA Damage in Genes of Proteins Modified during AD
DNA is vital to cellular function, therefore DNA oxidative damage could possibly be
one of the most important factors in the neuronal degeneration observed in AD subjects.
This study is the first to determine oxidative damage in the coding sequence of genes of
proteins affected during AD in subjects throughout the progression of AD. Oxidative
DNA damage was quantified using fpg mediated glycosylase activity and qPCR for the
three isoforms of voltage-dependent anion channel protein (VDAC)- VDAC1, VDAC2
and VDAC3. VDACs, also known as mitochondrial porins, are the most abundant
proteins in the mitochondrial outer membrane and principally function as voltagedependent pores in the mitochondrial membrane for transfer of substrates (pyruvate,
malate ATP, hemes, NADH, succinate and phosphate) used in oxidative phosphorylation
and electron transport chain pathways. The three isoforms, VDAC1, VDAC2 and
VDAC3, show an essentially conserved sequence but differ in abundance, size, function
and activity. VDAC1 is the most abundant isoform of the VDAC family followed by
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VDAC2 and then VDAC3. The VDAC isoforms were chosen for analysis because
previous studies show differential expression of protein levels for the three proteins in
AD. Yoo et al. (Yoo et al., 2001) reported a significant decrease in VDAC1 levels in the
frontal cortex and thalamus and a significant increase in VDAC2 protein levels in
temporal cortex in AD subjects compared to age-matched control subjects. Yoo et al. did
not report any changes in VDAC3 protein levels as it was not detected in the analyzed
samples (Yoo et al., 2001). Lovell et al. showed a statistically significant elevation in
VDAC1 protein levels, a trend towards significant increase in VDAC3 levels and no
change in VDAC2 levels in primary neuron cultures treated with Aβ (Lovell et al., 2005).
Based on these observations, we hypothesized there may be oxidative damage in the
coding sequences of VDAC1 and VDAC3 but not in that of VDAC2.
Comparison of oxidative damage in DNA isolated using the phenol-chloroform
extraction and extraction using a Qiagen DNeasy Tissue Kit showed 10-20% more
artifactual oxidation in DNA from the Qiagen DNeasy Tissue Kit. Thus the phenolchloroform extraction method was used to extract all DNA samples used in this project.
In the phenol-chloroform extraction method, 8-hydroxyquinoline was used as an
antioxidant additive to phenol to prevent artifactual oxidation. Furthermore, oxidation by
trace metals was prevented by chelation with EDTA during DNA isolation. The study
utilized tissue samples from brain specimens with short PMI (Table 2.1) to further reduce
the chances of artifactual oxidation. Levels of oxidative DNA damage were quantified
using the fpg enzyme, primers designed to encompass each gene’s coding sequence and
qPCR. The data obtained for this study were analyzed using the standard curve analysis
method for qPCR derived from 5 to 7-fold serial dilutions of genomic DNA from NC
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subjects. To prevent artifactual oxidation by freeze-thawing, new DNA samples were
isolated from tissue for each qPCR reaction. Primers for qPCR were designed to have
~50% GC ratio, 24 bp length, Tm of ~60 (±2) °C and an amplicon size of 175-285 for
maximum efficiency. The fluorescent dye SYBR Green which intercalates with dsDNA
was used to measure amount of product in the qPCR reaction.
Among the 8 amplicons studied for VDAC1, 3 amplicons including VDAC1D,
VDAC1H and VDAC1I showed no statistically significant changes in either the SMTG
or cerebellum. In contrast, VDAC1B, VDAC1C, VDAC1E and VDAC1G showed
statistically significant increases in % oxidative damage in SMTG of LAD subjects.
Levels of % oxidative damage were also significantly elevated in the SMTG of PCAD
subjects for VDAC1A, VDAC1C and VDAC1E. A trend towards a significant increase
was observed for VDAC1B in SMTG of PCAD subjects and for VDAC1E in SMTG of
MCI subjects. The cerebellum, where minimal AD pathology is observed, showed no
significant changes at any stage of disease progression suggesting a brain region
dependent differential distribution of oxidative DNA damage during the progression of
AD. There was significant oxidative damage in the VDAC1B, VDAC1C and VDAC1E
amplicons in the SMTG of DC subjects and in cerebellum of DC subjects for the
VDAC1B amplicon. This suggests oxidative damage in these two regions is probably not
AD-specific but is a shared characteristic of multiple neurodegenerative diseases. The
lack of detection of oxidative damage for any VDAC2 amplicon suggests VDAC2 is
minimally affected during the progression of AD or other neurodegenerative diseases
including FTD and DLB. VDAC3 is the smallest gene among the three and shows
oxidative damage only in one amplicon, VDAC3E, in the SMTG of LAD subjects.
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These data are supportive of our initial hypothesis. Lovell et al. showed a significant
increase in VDAC1 protein levels in Aβ-treated cultures and only a trend towards a
significant increase in VDAC3 protein levels and we hypothesized that maximum
oxidative damage would be seen in VDAC1 followed by some oxidation in VDAC3.
Overall, our studies also suggest oxidative DNA damage in enzymes affected during AD
occurs early in AD pathogenesis with more damage in areas with extensive AD
pathology. A common characteristic of the regions with more oxidative damage is the
presence of groups of multiple guanines. Prat et al. suggested that oxidation of one
guanine reduces the ionization potential of sequential guanines present thus promoting
increased oxidation (Prat et al., 1998).
At present, it is still unclear what effect genomic oxidation has on subsequent
transcription and translation processes. Previous studies show oxidative DNA damage
leads to mismatched base pairs (Cysewski and Olinski, 1999), strand breaks (Cullis et al.,
1996; Devasagayam et al., 1991) and protein crosslinking (Hickerson et al., 1999;
Kurbanyan et al., 2003; Nguyen et al., 2000) in nuclear and mitochondrial DNA. For
VDACs, an increase in oxidative damage seems to correlate with increased translation
and thus increased protein levels though the impact of this oxidative DNA damage on the
functionality of VDAC proteins is as yet unknown. To begin to try and understand the
effects of DNA oxidation on translated proteins, we chose to study IGF2, a small protein
with a 202 bp coding sequence. Varying ratios of 8-oxoguanine/guanine (10/90, 25/75,
35/65, 50/50, 75/25 and 0/100) were incorporated in the IGF2 coding sequence via PCR
reactions and resulting DNA transcribed and translated using a cell-free system. Protein
levels generated were quantified using Western blot analysis and showed a significant
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increase in IGF2 in all the samples with 8-oxoguanine incorporation, although there was
no clear concentration-based trend observed. This is similar to the data observed for
VDAC oxidative damage and protein levels (Lovell et al., 2005). A previous study by
Hailer-Morrison et al. showed an increase in binding affinity of the p50 subunit of the
transcription factor NF-κB on substitution of guanine by 8-oxogunanine at sites critical
for protein binding (Hailer-Morrison et al., 2003). Protein activity of IGF2 on the other
hand showed significant decreases in 8-oxoguanine incorporated samples compared to
the positive control sample. Again there was no concentration based trend observed for
enzyme activity with increasing amounts of 8-oxoguanine. A decrease in protein activity
could be due to the production of non-functional protein due to presence of oxidation in
the gene sequence and hence subsequent mistakes during transcription and translation.
4.2. Changes in DNA Repair Enzymes of BER Pathway in AD Subjects
An increase in oxidative base lesions could be due to inactivity/alterations of the
DNA repair enzymes or an increase in oxidative stress on DNA or a combination of both
factors (Dianov et al., 2001; Lovell et al., 2000; Wang et al., 2005; Weissman et al.,
2007). It is postulated that in age-related neurodegenerative diseases like AD, the DNA
repair system loses its capacity for repair resulting in accumulated oxidative DNA
damage (Lovell et al., 2000; Markesbery and Lovell, 2006; Moreira et al., 2008;
Weissman et al., 2007). In the brain, the BER pathway is the major pathway for repair of
small base modifications in DNA caused by oxidation, alkylation or deamination. The
BER pathway can primarily be broken down to five key steps: (1) recognition and
elimination of damaged base (2) excision of abasic site (3) removal of 5´-abasic terminal
fragment (4) gap filling with correct base and (5) ligation of the DNA strand. Based on
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the size of the excised nucleotide, the BER pathway is further divided into two subpathways: short-patch BER (single nucleotide excision) and long-patch BER (2-8
nucleotides excision). Multiple enzymes including appropriate DNA glycosylases
(OGG1, UNG etc.), endonucleases (APE1, FEN1), phosphatases, kinases, polymerases
(POLB, POLδ, POLε), PARP1, XRCC1, ligases (LIG1, LIG3) and auxillary factors (e.g.
p53, p21, PCNA, RPA) are required for the effective implementation of DNA repair via
the BER pathway (Fan and Wilson, 2005; Izumi et al., 2003; Kim and Wilson, 2012;
Parsons and Dianov, 2013). Multiple studies have reported alteration in enzymes of the
BER pathway in AD subjects although research has been more focused on the enzymes in
the early phase of BER specifically OGG1, UNG and APE1 (Coppede and Migliore,
2009; Davydov et al., 2003; Iida et al., 2002; Love et al., 1999; Lovell et al., 2000; Tan et
al., 1998; Weissman et al., 2007). This study is unique in the fact that changes in the
seven major enzymes of the BER pathway were studied in a single well-characterized
cohort of subjects throughout the progression of AD. In order to determine if the DNA
repair enzymes of the BER pathway were inactive or altered, custom PCR arrays and
quantitative reverse transcription polymerase chain reaction (qPCR), Western blot
analysis and enzyme activity assays were used to quantify changes in BER enzymes
(OGG1, UNG, APE1, POLB, FEN1, PARP1 and XRCC1).
Substrate-specific DNA glycosylases initiate the BER pathway by recognizing and
subsequently removing the impaired base. One of the major lesions of DNA oxidative
damage is the oxidation product of guanine, 8-hydroxyguanine which is primarily
removed by OGG1 in both nDNA (α-OGG1) and mtDNA (β-OGG1). OGG1 is the one of
the best characterized BER proteins but the regulation of OGG1 expression and function,
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and consequently its role in multiple diseases including cancer and AD is still being
investigated. Studies have suggested association of transcriptional regulation of the
OGG1 gene with expression of p53 and Zn depletion (Habib et al., 2008; Sharif et al.,
2012; Song et al., 2009; Youn et al., 2007). Our data showed no significant changes in
OGG1 gene expression, protein levels or nuclear OGG1 incision activity in the SMTG of
MCI subjects compared to NC. In contrast, Shao et al. showed a significant increase in
protein levels but a significant decrease in OGG1 activity in the SMTG of MCI subjects
compared to NC subjects (Shao et al., 2008; Weissman et al., 2007). In the current study,
we saw a statistically significant increase in fold change in gene expression of OGG1, a
corresponding statistically significant increase in OGG1 protein levels but no significant
changes in OGG1 incision activity in SMTG of PCAD subjects compared to NC subjects,
suggesting regulation of OGG1 transcription and translation as a result of injury
(oxidative damage) but functional inactivation of the protein. Shao et al. (Shao et al.,
2008) suggested that a decrease in OGG1 activity could be due to HNE (4hydroxynonenal, a by-product of lipid peroxidation) mediated aldehydic modification of
OGG1. There was a significant increase in gene expression in SMTG of LAD subjects
compared to NC subjects, but no corresponding change in protein level or incision
activity of OGG1. The contrast in gene expression levels, protein and activity levels in
the current study could be due to formation of modified protein more susceptible to
proteolytic degradation after translation from oxidatively damaged genes in a ROS rich
environment present in LAD subjects’ brain (Tanaka et al., 2007). In contrast, Lovell et
al. and others showed decreased OGG1 activity and protein levels in SMTG of LAD
subjects compared to NC subjects (Iida et al., 2002; Lovell et al., 2000; Weissman et al.,
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2007). No significant differences were observed in gene expression or protein activity in
SMTG of DC subjects but there was a significant decrease observed in protein levels
compared to NC subjects. Comparison of OGG1 gene expression, protein levels or
enzyme activity levels in the cerebellum showed no significant differences for any of the
subject groups studied which concurs with previous studies (Iida et al., 2002; Lovell et
al., 2000; Weissman et al., 2007).
UNG, another DNA glycosylase highly specific for removal of uracil lesions in
nuclear and mitochondrial DNA was also investigated in this study. Uracil can be
introduced into genomic DNA by deamination of cytosine to 5’- hydroxyuracil by ROS.
A significant decrease in UNG protein levels and activities in AD subjects compared to
NC subjects in multiple brain regions was reported by Weissman et al. (Weissman et al.,
2007). Our results show a significant increase (P < 0.05) in gene expression but no
corresponding change in protein levels of UNG in SMTG of MCI subjects compared to
NC subjects. UNG activities were significantly higher in the SMTG of MCI subjects
compared to NC subjects. There was a significant increase in gene expression but no
corresponding change in protein levels of UNG in SMTG of PCAD and LAD subjects
compared to NC subjects which could be attributed to modifications in the protein
sequence leading to abnormal structure during the translation process due to the presence
of oxidized bases in the protein coding sequence. Our study of UNG activity levels show
a significant increase in SMTG of PCAD and LAD subjects compared to NC subjects.
Previous studies show UNG activities can be enhanced by APE1 (Parikh et al., 1998)
which was also elevated in SMTG of PCAD and LAD subjects. For DC subjects, levels
of UNG gene expression were significantly elevated in SMTG although there were no
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corresponding changes in protein levels or activities compared to NC subjects. This
suggests alterations in UNG expression may not be AD-specific but may be a general
event associated with neurodegeneration and can be seen in other forms of dementia
including FTD and DLB. In the cerebellum, UNG gene expression levels and activity
levels showed no significant difference for any of the subject groups studied. UNG
protein levels on the other hand showed a significant increase in PCAD subjects in the
cerebellum but no changes for the other subject groups.
DNA glycosylases remove damaged bases in a DNA strand generating an
apurinic/apyrmidinic (AP) site also called a single strand break (SSB) site. APE1 cleaves
the AP site generated in the second step of the BER pathway creating a gap which is
filled by DNA polymerases. It has been postulated that this excision of the AP site is the
rate determining step of the pathway and that 95% of the excision can be attributed to
APE1 (Chen et al., 1991). APE1 also plays a critical role in conservation of gene
expression efficiency by regulating DNA binding capacity of multiple transcription
factors including p53, NF-κB and AP1 and acting as a transcriptional repressor of its own
gene and other genes including the PTH (parathyroid hormone) gene (Fritz, 2000; Izumi
et al., 1996). Fritz et al. suggests regulation of APE1 activities by posttranslational
modifications although further study is needed to elucidate the different physiological
functions and functional regulation of this highly complex multifunctional enzyme (Fritz,
2000; Fritz and Kaina, 1999). Protein-protein interactions with other enzymes in the BER
pathway could also contribute to inhibition/enhancement of APE1 function. Studies have
shown interactions between APE1 and multiple DNA glycosylases including OGG1 and
UNG. A significant increase in activity of both OGG1 and UNG was observed in the

166

presence of APE1 (Aliyev et al., 2005a; Aliyev et al., 2005b; Aliyev and Aliyev, 2005;
Hill et al., 2001; Parikh et al., 1998). Masuda et al. suggested that APE1 underwent
product inhibition and showed an increase in APE1 activity in presence of POLB
(Masuda et al., 1998). Similarly XRCC1, a scaffold protein involved in the BER
pathway, has been shown to stimulate APE1 activity by protein-protein interactions (Sak
et al., 2005; Vidal et al., 2001). Although multiple studies have shown physical
interaction of APE1 with POLB, FEN1 and p53, the effect of these interactions on APE1
functional regulation needs further investigation (Bennett et al., 1997; Dianova et al.,
2001; Gaiddon et al., 1999; Ranalli et al., 2002). It also remains unclear if the redox
functions of APE1 affect its endonuclease activity.
Multiple studies have shown an increase in APE1 nuclear immunostaining in the
cerebral cortex and hippocampus of AD subjects compared to NC subjects (Edwards et
al., 1998a; Edwards et al., 1998b; Marcon et al., 2009). In this study, we found no
significant changes in APE1 gene expression or protein levels in SMTG of PCAD or
LAD subjects compared to NC subjects. APE1 enzyme activities interestingly were
elevated in SMTG of both PCAD and LAD subjects compared to NC subjects. This
increased APE1 activity could be due to posttranslational modifications, protein-protein
interactions with other enzymes in the pathway or other as yet undiscovered regulatory
mechanisms. Previous studies have also suggested interactions between APE1 and OGG1
and UNG that affect enzymatic activity (Aliyev et al., 2005b; Aliyev and Aliyev, 2005;
Tengiz et al., 2005). Surprisingly, our data also showed significant reduction in APE1
activity levels in the cerebellum of PCAD and LAD subjects compared to those from NC
subjects although no corresponding changes had been observed in gene expression or
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APE1 protein levels indicating that changes in APE enzymatic activity could be brain
region specific. The decrease in APE1 activity could be due to posttranslational
modifications of APE1 such as phosphorylation, acetylation, ubiquitylation, poly(ADPribosyl)ation or HNE mediated aldehydic modification as observed for OGG1 (Fritz and
Kaina, 1999; Shao et al., 2008). This difference in activity levels in the SMTG (increase)
and cerebellum (decrease) could also be due to differential protein-protein interactions
with other BER proteins including glycosylases (OGG1, UNG), POLB, FEN1, PARP1
and XRCC1. We found no significant changes in APE1 expression in MCI subjects but
there was a statistically significant decrease in APE1 protein levels (but no corresponding
change in APE1 activity) in SMTG of MCI and DC subjects compared to NC subjects.
This increase in enzymatic activity could be due to the multifactorial reasons discussed
previously. The changes seen in DC subjects suggest changes in APE1 are not AD
specific but could possibly be present in other forms of dementia also.
The fourth enzyme investigated in this study was POLB. POLB is the primary
polymerase for gap filling in both the short-patch and long-patch version of BER
(Podlutsky et al., 2001a; Podlutsky et al., 2001b). The vital role played by POLB in fetal
growth and development can be deduced by the fact that POLB deficient mice show
embryonic lethality (Gu et al., 1994). Although multiple studies have suggested
posttranslational modifications including acetylation, methylation, ubiquitylation and
phosphorylation play a vital role in regulation of POLB activity and coordination of BER,
the functional impact of most of these modifications still needs to be elucidated (ElAndaloussi et al., 2007; El-Andaloussi et al., 2006; Hasan et al., 2002; Parsons et al.,
2011; Parsons et al., 2008). Parsons et al. suggested that availability of active BER
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enzymes including POLB is directly dependent on the number of DNA lesions present in
the cell. They suggested that excess POLB is sequentially ubiquitylated by the ubiquitin
ligases Mule and CHIP and then degraded via the proteasome pathway. In case of an
increase in amount of DNA lesions, higher amount of active POLB can be obtained by
inhibition of Mule activity by the protein ARF (Alternative Reading Frame) and/or
deubiquitylation of POLB by ubiquitin-specific proteases (USPs) (Chen et al., 2005;
Gallagher et al., 2006; Lee et al., 2005; Parsons et al., 2011; Parsons et al., 2008; Parsons
et al., 2009). Mule also regulates the activity of p53 which in turn interacts with multiple
BER proteins.
Previous studies have also shown that protein-protein interactions between POLB
and other proteins including APE1, PCNA, FEN1, PARP1, XRCC1, WRN, HMGB1,
p53, LIG1, LIG3, RPA, Rad9/Rad1/Hus1 (9-1-1 complex) and APC could help in the
regulation of POLB activity and selection between SP-BER and LP-BER (Goellner et al.,
2012; Yamtich and Sweasy, 2010). APE1 has been shown to stimulate POLB 5´-dRP
lyase activity (Bennett et al., 1997) while APC (Adenomatous polyposis coli) inhibits
POLB lyase activity (Balusu et al., 2007; Jaiswal et al., 2006; Narayan et al., 2005).
Enhanced BER activity observed in the presence of p53 could be due to the interactions
of POLB, p53 and APE1 as p53 seems to stabilize the POLB–AP–DNA complex in
presence of APE1 (Zhou et al., 2001). XRCC1, LIG1 and APC inhibit POLB strand
displacement synthesis thus promoting SP-BER (Balusu et al., 2007; Jaiswal et al., 2006;
Kubota et al., 1996; Narayan et al., 2005; Prasad et al., 1996). Though it has been
proposed that strand displacement synthesis by POLB is stimulated by FEN1, studies
suggest that the impact of the interactions between the two enzymes is more intricate and
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may depend on a number of factors including enzyme concentration and nature and
amount of substrate. (Balakrishnan et al., 2009; Pascucci et al., 2002; Pascucci et al.,
1999; Prasad et al., 2000). POLB strand displacement synthesis is also enhanced by
PARP1, the 9-1-1 complex and WRN (Werner syndrome, RecQ helicase) (Harrigan et
al., 2003; Prasad et al., 2001; Toueille et al., 2004). POLB has also been shown to
interact with multiple other proteins like HMGB1 (high mobility group box 1) and OGG1
but the functional impact of these interactions is not yet fully understood (Braithwaite et
al., 2010; Prasad et al., 2007).
Weissman et al. reported a decrease in POLB protein and activity levels in the
inferior parietal lobule (IPL) and cerebellum of AD subjects (Weissman et al., 2007).
Copani et al. showed a decrease in POLB expression in midtemporal cortex of AD
subjects (Copani et al., 2006). Our data is in contrast to both these studies. There were no
changes in POLB expression levels in SMTG of MCI subjects but there was a significant
decrease in protein levels and surprisingly an increase in POLB enzymatic activity. In
this study, we found that there was a statistically significant increase in gene expression
in SMTG of PCAD subjects, no corresponding changes in POLB protein levels and
interestingly a significant increase in POLB activity. POLB activity levels were also
elevated in the cerebellum of PCAD subjects although POLB expression and protein
levels were unchanged. It has been proposed that a fraction of POLB produced by the
cells is stored in the cytoplasm in its mono-ubiquitylated form and is activated by
deubiquitylation when required which in turn depends on the number of DNA lesions and
the activity of the enzymes in the early phase of BER (Goellner et al., 2012; Parsons et
al., 2011; Woodhouse et al., 2008). This storage mechanism, effects of post translational
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modifications, and protein-protein interactions with other BER proteins could account for
the discrepancy between gene expression, protein levels and levels of enzymatic activity
that we observed. There were no changes in POLB gene expression, protein levels or
enzyme activity in the cerebellum of MCI subjects. In the SMTG, there was a significant
increase in POLB expression levels, a corresponding increase in protein levels but no
analogous changes in enzyme activity in LAD subjects. No changes in POLB gene
expression, protein levels or enzyme activity were observed in the cerebellum of LAD
subjects. In case of DC subjects, gene expression, protein levels and POLB activity levels
were unaltered in the SMTG. Although POLB expression levels were significantly higher
in the cerebellum of DC subjects there were no corresponding changes in protein
expression and enzymatic activity. In the SMTG, alterations in POLB enzyme levels
seem to be an AD-specific event. The changes in POLB in the cerebellum seem to be a
more generalized event in neurodegeneration rather than being specific to AD. These
results again seem to point to a brain region-specific response to oxidative damage and
alteration of BER enzymes.
FEN1 is the major endonuclease involved in LP-BER and cleaves the 5´-flap
structure produced by strand-displacement synthesis. FEN1 activity on flap containing
substrates has been shown to be stimulated by multiple proteins including POLB,
PARP1, LIG1, PCNA, WRN, BLM,

HMGB1, Rad9/Rad1/Hus1 complex and even

APE1. The interaction of APE1, PARP1 and POLB with FEN1 seems to be a vital factor
in stimulation of LP-BER (Brosh et al., 2001; Dianova et al., 2001; Friedrich-Heineken et
al., 2005; Prasad et al., 2000; Prasad et al., 2001; Prasad et al., 2007; Ranalli et al., 2002;
Sharma et al., 2004; Tom et al., 2000; Wu et al., 1996). FEN1 is regulated not just by
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protein-protein interactions but also by posttranslational modifications. Phosphorylation
of FEN1 by cyclin-dependent kinase1 (Cdk-1)-Cyclin A decreases FEN1 activity and
inhibits interaction of FEN1 with PCNA (Henneke et al., 2003). p300 acetylates FEN1
which also leads to reduced FEN1 activity (Hasan et al., 2001). We saw no significant
changes in FEN1 expression, protein levels or activity levels in SMTG or cerebellum of
MCI subjects. Although there were no changes in gene expression, protein levels were
significantly elevated and FEN1 activity levels were significantly decreased in SMTG of
PCAD subjects. Surprisingly, the same trend of no change in gene expression, an increase
in protein level and a decrease in enzyme activity was observed in the SMTG of LAD
subjects and the cerebellum of DC subjects. Translational and posttranslational regulation
by protein-protein interactions and posttranslational modifications could account for this
trend in FEN1 protein and activity levels. In the cerebellum, no changes in gene
expression, protein levels and FEN1 activity were seen in PCAD and LAD subjects. In
SMTG of DC subjects, we saw no significant changes in gene expression but observed a
decrease in protein level and a corresponding decrease in enzyme activity. Thus, changes
in FEN1 seem to be a part of the neurodegenerative process rather than just being AD
specific. Different brain regions also seem to have differential distribution of FEN1
alterations.
Although the complete functionality of PARP1 still needs to be elucidated, it has
been proposed that PARP1 plays an extremely critical role in BER as recruiter for other
BER proteins to the damaged site and for recognition of the single stranded break (SSB)
site. Besides BER, PARP1 is also involved in other cellular processes including
transcriptional regulation, cell differentiation, chromatin modification, necrosis and
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apoptosis. It has been proposed that PARP1 activity is also regulated by multiple
posttranslational modifications including phosphorylation, poly(ADPribosylation),
ubiquitylation, sumoylation and acetylation (Strosznajder et al., 2012). The idea that
PARP1 is a recruiter protein for the latter half of BER is perpetuated by the interaction of
PARP1 with multiple proteins of BER pathway including POLB, FEN1, XRCC1 and
LIG3 probably by poly(ADP-ribosyl)ation of these proteins by PARP1. XRCC1 was
reported to decrease PARP1 activity (El-Khamisy et al., 2003). Though it is known that
PARP1 interacts with multiple other proteins, the functional impact of these interactions
on PARP1 activity remains unclear. PARP1 activity has been reported to increase up to
500 fold upon binding to damaged DNA (Adamczyk et al., 2005; Strosznajder et al.,
2012). Grube et al. and Muiras et al. found a positive correlation between PARP1 activity
and longevity with maximum activity being observed in cells from centenarians though
there was no change in PARP1 protein levels (Burkle et al., 1992; Grube and Burkle,
1992; Muiras et al., 1998). Previous studies have reported an increase in PARP1 activity
and accumulation of its reaction product, PAR (poly(ADP-ribose)) in frontal and
temporal lobes, skin fibroblasts and lymphoblasts in AD patients (Cecchi et al., 2002;
Love et al., 1999). PARP1 polymorphisms are also being associated as a risk factor for
AD (Infante et al., 2007; Liu et al., 2010).
Our data showed no significant differences in PARP1 expression, protein levels or
protein activity in the SMTG or cerebellum of MCI subjects. Although there were no
significant changes in gene expression and enzymatic activity in SMTG of PCAD
subjects, there was a significant decrease in protein levels. Surprisingly, in the cerebellum
of PCAD subjects, there was an increase in protein activity but no analogous changes in
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gene expression and protein levels. In the SMTG of LAD subjects, there was a significant
increase in gene expression and a significant decrease in protein levels which could be in
response to increased pathologic changes. There was a significant increase in enzyme
activity in SMTG of LAD subjects which is consistent with the study by Adamczyk et al.
that reported increased PARP1 activity on binding to damaged DNA (Adamczyk et al.,
2005; Strosznajder et al., 2012). No significant differences in fold change in PARP1
expression levels were observed in the cerebellum of LAD subject but like in the SMTG,
protein levels were significantly decreased and activity levels were significantly elevated.
The same pattern of no change in gene expression, lower protein levels and higher
enzymatic activity was seen in the cerebellum of DC subjects indicating that PARP1
alterations are present in the seemingly non-vulnerable cerebellar region and that these
changes are a part of neurodegenration rather than just AD. No changes in gene
expression, protein levels and activity were observed in SMTG of DC subjects.
It is proposed that XRCC1 acts as a scaffold protein in the BER pathway as XRCC1
reacts with multiple enzymes of BER but has no apparent enzyme activity. Proteinprotein interactions have been reported between XRCC1 and almost all the major
enzymes involved in BER indicating the vital role this protein plays in genomic stability.
XRCC1 interacts with and affects the activity of DNA glycosylases, APE1, POLB,
PARP1, PCNA, LIG1 and LIG3 (El-Khamisy et al., 2003; Kubota et al., 1996; Sak et al.,
2005; Strom et al., 2011; Thompson and West, 2000; Vidal et al., 2001) though the effect
of these proteins on XRCC1 activity is still not known. Fisher et al. reported down
regulation of XRCC1 accumulation at site of DNA damage by the PAR degradation
enzyme, poly(ADP-ribose) glycohydrolase (PARG) thus affecting the scaffold action of

174

XRCC1 (Fisher et al., 2007). We were unable to measure XRCC1 activity as XRCC1 has
as yet no known enzymatic function. In SMTG of MCI subjects although no changes in
gene expression were observed, there was a significant increase in protein levels. The
same trend was observed in SMTG of PCAD subjects and cerebellum of DC subjects.
There were no changes in gene expression and protein levels seen in the SMTG of LAD
and DC subjects, cerebellum of MCI, PCAD and LAD subjects. Increases in XRCC1
mRNA and protein levels after damage to DNA were reported by Yacoub et al. via
activation of the XRCC1 promoter by the transcription factor EGF-2 (Yacoub et al.,
2003). It has been proposed that like the other enzymes in BER, XRCC1 is also regulated
by posttranslational modifications including ubiquitylation, phosphorylation and PARP1mediated poly(ADP-ribosyl)ation (El-Khamisy et al., 2003; Parsons et al., 2008; Strom et
al., 2011; Whitehouse et al., 2001). XRCC1 deficiency has been shown to decrease BER
repair capacity indicating that overall BER functionality may depend to some extent on
available active XRCC1 (Brem and Hall, 2005; Iftner et al., 2002; Vidal et al., 2001).
Overall, our findings suggest gene expression of DNA repair pathway enzymes is
significantly affected in patients with AD and some of these changes can be seen even in
the initial stages of AD (MCI and PCAD). Significant alterations in BER enzymes in the
cerebellum, a brain region typically considered as an internal control in AD indicates that
oxidative damage and consequently the repair response could be a global event in AD. A
few previous studies have also shown disease related changes in the cerebellum. Braak et
al. and Yamaguchi et al. showed diffuse amyloid plaques in the cerebellar cortex of AD
subjects (Braak et al., 1989; Yamaguchi et al., 1989). A significant decrease in volume of
the molecular and granular layers of AD subjects was observed by Wegiel et al. (Wegiel
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et al., 1999). Thomann et al. (Thomann et al., 2008) showed a decrease in volume of the
posterior cerebellar regions in AD subjects. This study also suggests that changes in BER
enzymes could be an event common to neurodegeneration rather than an AD-associated
event. The increase in gene expression seen with these proteins could be a compensatory
response as the disease progresses. Protein-protein interactions between the various BER
proteins and between BER proteins and other proteins like p300, p53 and HMGB1, and
posttranslational modifications including ubiquitylation, phosphorylation and PARP1mediated poly(ADP-ribosyl)ation could account for the alterations in protein levels and
enzymatic activity. The changes observed in this study will hopefully provide a platform
for further studies investigating the function, regulation and interactions of the enzymes
of the complex BER pathway and thus offer further understanding of the ramifications of
oxidative stress during the progression of Alzheimer’s disease.
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Chapter 5: Conclusions
Demographics show that decreasing fertility rates and increased life expectancy have
led to an aging world population. Approximately 800 million people were aged 65 and
older in 2010 and this number is estimated to grow to 2 billion people by 2050 (22% of
world’s population) (2010; Bloom et al., 2010; UNPD, 2011). Therefore there is an
increasing need for awareness, diagnosis and treatment of age-related diseases including
cardiovascular diseases, dementia and Alzheimer’s disease. Batsch et al. estimated that in
2010, there were 36 million people suffering from dementia worldwide with a global cost
of $604 billion (Batsch, 2012). Approximately 5 million of these AD patients live in the
US with the number of AD patients expected to triple to 13.8 million by the year 2050 in
the US alone (Thies and Bleiler, 2011, 2013). The cost of AD is an estimated $203 billion
in 2013 projected to increase to $1.2 trillion in 2050. This number does not take into
account the financial, emotional and physical toll the disease puts on the 15.4 million
caregivers who provided an estimated 17.4 billion hours of unpaid care in 2012.
In spite of the increasing threat of financial and health crises that can be created by
AD, early detection and treatment of the disease is still in its infancy. Most current drug
therapeutics

available

to

patients

at

present

are

symptomatic

rather

than

curative/preventive. Although MCI patients are easily diagnosed by a skilled physician,
detection of PCAD patients ante-mortem is still challenging. Early detection of AD
would help patients be better prepared and possibly in the future have a better chance of
treatment. As the exact etiology of AD is still unknown and seems to be multifactorial, it
has been difficult for researchers to provide efficient stratagems for treatment. Studies
have suggested oxidative stress plays a major role in AD pathogenesis and could thus be
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a target for therapeutic strategies (Cooke et al., 2003; Lovell and Markesbery, 2007a;
Markesbery, 1997b; Markesbery and Carney, 1999). Recent studies have shown an
increase in markers of oxidative damage of biomolecules including proteins, lipids and
nucleic acids in AD subjects (Gabbita et al., 1998; Keller et al., 2005; Milne et al., 2005;
Williams et al., 2006). DNA oxidative damage is extremely critical in post-mitotic cells
like neurons as it could lead to genomic instability, loss of fidelity during transcription
and translation, and ultimately cell death. While previous studies have shown an increase
in oxidative DNA damage in AD subjects (Gabbita et al., 1998; Lovell and Markesbery,
2001; Wang et al., 2008), it is not yet clear if genomic oxidation is a global, random
phenomenon or is it targeted to specific areas of the genome. Accumulation of oxidative
DNA damage in AD brains could be due to two factors: an increase in ROS production or
breakdown of the repair mechanisms especially the BER pathway (main repair pathway
for oxidative damage in brain). The purpose of this study was twofold: (A) to determine
if genomic oxidation was targeted to representative genes that show protein alterations
during the progression of AD and (B) to determine if increased oxidative DNA damage
was a result of a decrease in any of the seven major enzymes of the BER pathway during
AD progression, in a single well-characterized cohort of samples.
We hypothesized that oxidative DNA damage is not a random global event but is
targeted to specific areas of coding sequences of proteins that ultimately show alterations
in AD. To study this, we focused our analyses on the three isoforms of the mitochondrial
porin protein, VDAC. VDAC was the ideal candidate for this study as the three forms
differ in abundance, size and activity, and are altered differentially in the AD brain.
Lovell et al. (Lovell et al., 2005) reported a significant increase in levels of VDAC1, a
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trend towards significant increase in VDAC3 and no changes in VDAC2 in Aβ-treated
primary neuronal cultures. Based on our hypothesis, we should see the maximum
increase/decrease in oxidative damage in VDAC1, some change in VDAC3 and no
oxidative damage in VDAC2 coding sequences. Our results support the hypothesis. We
saw an increase in oxidative damage in four areas of the VDAC1 coding sequence and
one area of the VDAC3 coding sequence in the SMTG of subjects with AD. No oxidative
damage was observed in the VDAC2 coding sequence in the SMTG of MCI, PCAD,
LAD and DC subjects. Study of the oxidative damage in the 3 VDAC isoforms in tissue
specimens from diseased control (FTD and DLB) subjects suggests that oxidative
damage in VDAC is a global event associated with neurodegeneration rather than just
being AD-specific. We did not see changes in the cerebellum for any of the three
isoforms indicating a region-specific attack by ROS on VDAC. It would be interesting to
see if this model is replicated for other proteins that show altered levels/activity during
AD. As VDAC has no known enzymatic function, we could not measure its activity. It
would have been instructive to see if increased genomic oxidation leads to changes in the
functionality of the proteins. We observed that when we introduced 8-oxoguanine into a
gene sequence (IGF2), there were significant changes in protein levels and activity which
would indicate that genomic oxidation leads to changes in transcription and translation.
This experiment was unique as the effect of oxidative stress on transcription and
translation was studied for the first time using a cell free system.
This oxidative damage seen can be as a result of a breakdown in the DNA repair
mechanisms in the brain. The second part of this study focused on investigating if
alterations occur in gene expression, protein levels and protein activity levels in the 7
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major enzymes involved in the BER pathway in an AD brain. The enzymes studied
included OGG1 (major DNA glycosylase for removal of 8-oxoguanine), UNG (uracil
DNA glycosylase), APE1 (accounts for 95% endonuclease activity), POLB (major DNA
polymerase),

FEN1

(major

endonuclease

in

long

patch

BER),

PARP1

(poly(ADP)ribosylation and binding to SSbs) and XRCC1 (scaffold protein). Studies
show that null mutation in APE1, POLB, FEN1, PARP1 and XRCC1 are embryonically
lethal in mice indicating the vital role these enzymes play in cellular viability and
development (Sobol et al., 1996; Tebbs et al., 1999; Woodhouse and Dianov, 2008; Wu
et al., 1996; Xanthoudakis and Curran, 1992). The understanding of the BER pathway is
further complicated by the fact that these enzymes are regulated by multiple proteinprotein interactions and posttranslational modifications. The functional impact of these
interactions on some of the BER enzymes is still unknown. Some BER proteins like
APE1 and PARP1 are also involved in other cellular pathways making it difficult to fully
understand how they are regulated. The study of BER enzymes in AD has mainly focused
on OGG1 with relatively few studies of APE1, UNG and POLB. Surprisingly all seven
enzymes have not yet been studied in a well-characterized cohort in brain tissue
specimens from the SMTG and cerebellum of MCI, PCAD, LAD and DC subjects. We
did not see a direct correlation between gene expression, protein levels and protein
activity for most of the enzymes which is understandable considering the complexity of
the BER pathway and the multitude of interactions each protein undergoes. We saw no
changes in gene expression for any of the proteins in SMTG of MCI subjects. Protein
levels, on the other hand, were altered for APE1, POLB and XRCC1, and protein activity
levels were significantly increased for UNG and POLB in SMTG of MCI subjects. A
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significant increase in gene expression was observed for OGG1, UNG and POLB in
SMTG of PCAD subjects. Change in protein levels was seen for OGG1, FEN1, PARP1
and XRCC1 and change in protein activity levels were observed for UNG, APE1, POLB
and FEN1 in SMTG of PCAD subjects. In SMTG of LAD subjects, changes were seen in
OGG1, UNG, POLB and PARP1 expression. Protein levels were altered for POLB,
FEN1 and PARP1 and protein activity levels for UNG, FEN1 and PARP1 in SMTG of
LAD subjects. Changes were also observed in UNG gene expression; OGG1, APE1 and
FEN1 protein levels; and FEN1 protein activity levels in SMTG of DC subjects
indicating that alterations in BER enzyme especially the glycosylases and endonucleases
could be an event associated with neurodegeneration. The results of the BER pathway
analysis are discussed in more detail in Chapters 3 & 4. As some of these enzymes are
also involved in other pathways, the alterations could also be due to interactions other
than during BER. For example, we saw an increase in PARP1 activity in LAD subjects
which implies an increase in BER activity but extensive PARP1 activation can also lead
to neuronal death. Thus, the biological significance of all these changes in AD
pathogenesis still needs to be elucidated. Some of the effects of protein-protein
interactions and posttranslational modifications observed with BER enzymes might be
better understood through gene expression, protein level and activity studies in
appropriate mouse models. Because APE1, POLB, PARP1, XRCC1 and FEN1 deficient
mice show embryonic lethality, the effect of the deficiency of these enzymes can be
studied using lentivirus mediated knockdown in mice. We hope the current study will
contribute to the understanding of BER enzymes in AD. Expectantly, understanding the
changes in BER enzymes will open the platform for identification of novel therapeutic
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strategies in AD. Inhibitors to some of the enzymes including APE1 and PARP1 are
already either in use to treat cancer patients or are in clinical trials. Recently, PARP1
inhibitors that assuage ischemic brain injury have also been introduced. Thus, as these
enzymes are already therapeutic targets for other diseases, hopefully it would be less
challenging to go from basic research to develop clinical trials as compared to completely
unexplored targets. Most studies of the BER pathway in AD have focused on the
glycolysases, especially OGG1. Very few studies are available that evaluate changes in
XRCC1 which may be a critical lynchpin of BER. XRCC1 acts as a scaffold protein and
also interacts with almost every protein in the BER pathway. Although the effect of
interactions between XRCC1 and other BER proteins is unclear there is a strong effect
on enzymatic activity at least for some enzymes (APE1, PARP1). This study showed that
XRCC1 protein levels were significantly lower in the disease groups, which could be one
of the major reasons for decreased BER repair capacity in AD seen by multiple studies.
Although more studies are needed to completely understand the role of XRCC1 in BER it
is possible that activation of XRCC1 could possibly lead to an increase in repair of DNA
oxidative damage making this an interesting novel target for therapeutic strategies.
The cerebellum is usually treated as an internal control in the AD brain as it has less
AD-associated pathology. Although our studies didn’t show changes in oxidative damage
in the VDAC isoforms, we saw significant changes in BER enzymes in the cerebellum.
Some of the changes were in marked contrast to the changes observed in the SMTG
indicating a region specific response. For example, while there was no difference in
PARP1 activity in the SMTG of PCAD and DC subjects, there was a significant elevation
observed in the cerebellum of these subjects. So the data from this study suggest that not
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only is BER pathway affected during the process of neurodegeneration in general, the
BER enzymes show a brain-region specific response even in the absence of substantial
disease pathology.
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